JPH0457646B2 - - Google Patents
Info
- Publication number
- JPH0457646B2 JPH0457646B2 JP57114150A JP11415082A JPH0457646B2 JP H0457646 B2 JPH0457646 B2 JP H0457646B2 JP 57114150 A JP57114150 A JP 57114150A JP 11415082 A JP11415082 A JP 11415082A JP H0457646 B2 JPH0457646 B2 JP H0457646B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- drug
- animals
- days
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 35
- -1 acyl ester Chemical class 0.000 claims description 16
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 111
- 229940079593 drug Drugs 0.000 description 62
- 239000003814 drug Substances 0.000 description 62
- 229940125904 compound 1 Drugs 0.000 description 57
- 206010028980 Neoplasm Diseases 0.000 description 43
- 238000012360 testing method Methods 0.000 description 40
- 230000034994 death Effects 0.000 description 28
- 231100000517 death Toxicity 0.000 description 28
- 238000011282 treatment Methods 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 230000004083 survival effect Effects 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 229940126214 compound 3 Drugs 0.000 description 13
- 125000002252 acyl group Chemical group 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 10
- 206010070863 Toxicity to various agents Diseases 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 7
- IXDAHPLEDYPEFV-FDYHWXHSSA-N [(2r,3r,4r,5r)-3,4-diacetyloxy-5-(4-carbamoyl-1,3-thiazol-2-yl)oxolan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1C1=NC(C(N)=O)=CS1 IXDAHPLEDYPEFV-FDYHWXHSSA-N 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 150000003857 carboxamides Chemical class 0.000 description 6
- 208000003747 lymphoid leukemia Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229960000329 ribavirin Drugs 0.000 description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 6
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FVRDYQYEVDDKCR-RKEPMNIXSA-N 2-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC(C2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-RKEPMNIXSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 3
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- HXTLABRDNBUHHP-FNCVBFRFSA-N [(2r,3s,4r,5r)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl acetate Chemical compound O[C@@H]1[C@H](O)[C@@H](COC(=O)C)O[C@H]1C1=NC(C(N)=O)=CS1 HXTLABRDNBUHHP-FNCVBFRFSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- IXRAQYMAEVFORF-UTLNTRLCSA-N (3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IXRAQYMAEVFORF-UTLNTRLCSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VPZQHLQWZJETBU-SKKKGAJSSA-N 2-[(2r,3r,4r,5r)-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolan-2-yl]-n-ethyl-1,3-thiazole-4-carboxamide Chemical compound CCNC(=O)C1=CSC([C@H]2[C@@H]([C@H](OCC=3C=CC=CC=3)[C@@H](COCC=3C=CC=CC=3)O2)OCC=2C=CC=CC=2)=N1 VPZQHLQWZJETBU-SKKKGAJSSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 239000005643 Pelargonic acid Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000034940 Undiagnosed disease Diseases 0.000 description 1
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000005131 dialkylammonium group Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- WUFIZLJHBHJOHX-UHFFFAOYSA-N ethyl acetate;propan-1-ol;hydrate Chemical compound O.CCCO.CCOC(C)=O WUFIZLJHBHJOHX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-O octylazanium Chemical compound CCCCCCCC[NH3+] IOQPZZOEVPZRBK-UHFFFAOYSA-O 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000005208 trialkylammonium group Chemical class 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ãã®åºé¡ã¯1980幎12æ15æ¥æåºããïŒâβâ
âãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢
ããããã³é¢é£ååç©ã«ããæªæ§è
«çã®æ²»çãšã
ãè¡šé¡ã®ç§ã®æªæ±ºã®åºé¡ç¬¬216197å·ã®äžéšåç¶ç¶
ã§ããããã€ãã®å
šéšã®é瀺ãããã§ã¯åç
§ãšã
ãŠèšèŒããã
æ¬çºæã¯ååç©ïŒâβââãªããã©ãã·ã«ã
ã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããããã³é¢é£èªå°
äœããšãã°ãã®ãšã¹ãã«ãçšããŠã®ã€ã³ãŽã€ãã«
ãããæªæ§è
«çã®æ²»çãžã®éã瀺ãããã®ã§ã
ãã
人ããã³åç©ã«ãããæªæ§è
«çã®æå¶ã«ããŸã
å®çŸãããªãç®æšãšããŠååšããããã®æ°å幎ã®
éã«ãæªæ§ïŒmalignacyïŒã«ã€ããŠã®ç解ã¯ãã
ãŸããé²æ©ãéãããããããªããæªæ§çŸæ£ç¶æ
ã®åŸæã¯ããŸã å®çŸããŠããªãã
æªæ§è
«çã«èŠãã人éããã³ä»ã®æçšãªåç©çš®
åæ¹ã«å¯Ÿããäžè¬çæ³ãšããŠçŸåšçœ¹æ£åç©ã®è
«ç
ã®å€ç§çåé€ãå±ææŸå°ç·çæ³ãããã³ãã®åç©
ãžã®ååŠçæ³å€æäžã«ããååŠçæ³ããããæªæ§
è
«çã«çœ¹æ£ããå®ã«å€ãã®æ£è
ã®æ»ã¯æåã®è
«ç
ã«ãããã®ã§ã¯ãªãã代ããã«æåã®è
«çã宿䞻
ã®æ¬¡ã®éšäœãžè»¢ç§»ããããšã«ãããã®ã§ãããã
ããæåã®è
«çãæ©æã«çºèŠãããã°ããããé
åžžã¯å€ç§ãæŸå°ç·ãããã¯ååŠçæ³åã¯ãããã®
䜵çšã«ãã€ãŠé€å»ãåŸããããããªãããããã
æåã®è
«çã®è»¢ç§»çŸ€èœãçºèŠãããã€é€å»ããã
ãšã¯éåžžã«ãããããããããã®äžæååŠçœ®ãæ·±
å»ãªå»åŠåé¡ãšãªã€ãŠããã
è
«çã¯éåžžè¯æ§åã¯æªæ§ãšããŠã®ããããã«å
é¡ããããæªæ§è
«çã¯åšèŸºçµç¹ãžã䟵å
¥ãããã€
転移ã«ãã€ãŠé¢ããéšäœã«è»¢ç§»å¢æ®ãããã®èœå
ã«ããè¯æ§ãšèå¥ããããããåšå®ã¯ä»ãããã
ã転移ããããããã®çŸ€ã«å«ãŸãããã®ã«ã¯èºã
è³ãèèãåµå·£ããã³å¯è
ããããããã«ã¯æå
ã®è
«çã«å¯Ÿããå€ç§ããã³æŸå°ç·ã¯ããå Žåã«ã¯
å®éã«ã¯è»¢ç§»ãä¿é²ãããŠããŸããšããããšã瀺
åãããŠããã
çŸåšã®ççæ³ãæªæ§è
«çãã®è»¢ç§»ãæå¶ã§ããª
ãç¹ããèããŠãä»å ååŠçæ³å€ã®å¿
èŠæ§ãååš
ããããšã¯æããã§ããã
ãããã¢ãŸãŒã«ïŒ£âãã¯ã¬ãªã·ãã®åæãšæãŠ
ã€ã«ã¹æŽ»æ§ãšããè¡šé¡ã®çŽé¢ïŒãžãšãŒã»ã¡ãã»ã±
ã ã»ïŒJ.Med.Chem.ïŒ1977ã第20巻第2256å·ïŒã«
ç§ãšç§ã®ååè
éã¯ãååç©ïŒâβââãªãã
ã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ãããã
ã³ïŒâïŒïŒïŒïŒïŒïŒâããªââã¢ã»ãã«âβâ
âãªããã©ãã·ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ãã
ã·ã¢ããã®åæãªãã³ã«ã€ã³ãŽã€ããã«ãããè©Š
éšç³»ã«ãããïŒçš®ã®ãŠã€ã«ã¹ãïŒååçŽå
ç¹ãŠã€
ã«ã¹ãïŒåãã©ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ãããŠïŒ
åã©ã€ããŠã€ã«ã¹ããçšããŠè¡ã€ãã€ã³ãŽã€ãã
ã«ãããäºåæãŠã€ã«ã¹æŽ»æ§ã«ã€ããŠèšèŒããŠã
ããååç©ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒ
ã«âïŒâã«ã«ããã·ã¢ããã®ãããïŒçš®ã®ãŠã€ã«
ã¹ã«å¯Ÿããã€ã³ãŽã€ããã§ã®æŽ»æ§ã¯åã«ç·©åã§ã
ã€ããååç©ïŒâïŒïŒïŒïŒïŒïŒâããªââã¢ã»
ãã«âβââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«âïŒ
âã«ã«ããã·ã¢ããã«é¢ããŠã¯ãåã«ç·©åãªæŽ»æ§
ã¯ïŒååçŽå
ç¹ãŠã€ã«ã¹ã§èŠããããïŒåãã©ã€
ã³ãã«ãšã³ã¶ãš13åã©ã€ããŠã€ã«ã¹ã§ã¯æŽ»æ§ã¯èŠ
ãããªãã€ããåèšã®ããåšçžã€ã³ãŽã€ããæãŠ
ã€ã«ã¹æŽ»æ§ã¯èŠãããããå
šããããšå察ã«ãïŒ
âβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«
ããã·ã¢ããããã³ïŒâïŒïŒïŒïŒïŒïŒâããªâ
âã¢ã»ãã«âβââãªããã©ãã·ã«ïŒãã¢ãŸãŒ
ã«âïŒâã«ã«ããã·ã¢ããåæ¹ã®ã€ã³ãŽã€ãæãŠ
ã€ã«ã¹è©Šéšã¯ãè©Šéšåç©ã®æ»ã®æ°ã«ãã€ãŠå€å®ã
ããšããé°æ§ã§ãã€ãããã®ã€ã³ãŽã€ãè©Šéšã§
ã¯ãïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒ
âã«ã«ããã·ã¢ããããã³ïŒâïŒïŒïŒïŒïŒïŒâã
ãªââã¢ã»ãã«âβââãªããã©ãã·ã«ïŒã
ã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããåæ¹ã§çšãã被
æ€åç©æ»ã®æ°ã¯ããã©ã·ãŒã察ç
§åç©æ»ã®æ°ãšå
ããåã¯ãã以äžã§ãã€ããããååç©ïŒâβâ
âãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«ããã·
ã¢ããããã³ïŒâïŒïŒïŒïŒïŒïŒâããªââã¢ã»
ãã«âβââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«âïŒ
âã«ã«ããã·ã¢ããã®åæ¹ãšãæçšãªã€ã³ãŽã€ã
æãŠã€ã«ã¹æŽ»æ§ã¯èšŒæãããªãã€ãããšã瀺ãã
ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâ
ã«ã«ããã·ã¢ããããã³ïŒâïŒïŒïŒïŒïŒïŒâããª
ââã¢ã»ãã«âβââãªããã©ãã·ã«ïŒãã¢
ãŸãŒã«âïŒâã«ã«ããã·ã¢ããåæ¹ã®äžèšã€ã³ãŽ
ã€ããã§ã®æãŠã€ã«ã¹è©Šéšã«é¢ããŠã¯ããããã®
ååç©ãæ¢ç¥æãŠã€ã«ã¹ååç©ãªãããªã³
ïŒRIBAVIRIN
ïŒãéœæ§ã®æãŠã€ã«ã¹æŽ»æ§ãæ
ããŠãããŠã€ã«ã¹ã«å¯ŸããŠè©ŠéšãããïŒâβâ
âãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢
ããã®ãããè©ŠéšãŠã€ã«ã¹ã«å¯Ÿããäºåã€ã³ãŽã€
ããåšçžæŽ»æ§ã®ç¹ããã¿ãŠãïŒâβââãªãã
ã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããã®æŽ»
æ§ã¹ãã¯ãã«ã¯ååç©ãªãããªã³
ã®æŽ»æ§ã¹ãã¯
ãã«ãšåãã§ããããšæãããããªãããªã³
ã¯
掻æ§ãªã€ã³ãŽã€ããæãŠã€ã«ã¹å€ããã³ã€ã³ãŽã€
ãæãŠã€ã«ã¹å€ãããããšãç¥ãããŠããããŸã
ããã«æãããªæè
«ç掻æ§ã¯ç€ºããªãããšãç¥ã
ããŠãããããã«ããªãããªã³
ã®ããèªå°äœã
ãšãã°ãã®5â²âã¢ããã¹ããšãŒãã¯ãŸãæè
«çå
åç©ãšããŠäžæŽ»æ§ã§ããããšãç¥ãããŠãããïŒ
âβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«
ããã·ã¢ããã®äºåã€ã³ãŽã€ããæãŠã€ã«ã¹æŽ»æ§
ããªãããªã³
ã®ãããšæ¯èŒããŠãïŒâβââ
ãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ã
ãã¯ãªãããªã³
ãšåãéœæ§ã®ã€ã³ãŽã€ãæãŠã€
ã«ã¹æŽ»æ§ãšé°æ§ã®æè
«ç掻æ§ãåããã®ã§ããã
ãšèããã®ã¯çã«ããªã€ãŠãããå
šãããã«åã
ãŠãååç©ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒ
ã«âïŒâã«ã«ããã·ã¢ããã¯æçšãªã€ã³ãŽã€ãæ
ãŠã€ã«ã¹æŽ»æ§ãæããããããŠå®ã«äºæ³ãããªã
ããšã«éœæ§ã®æè
«ç掻æ§ã瀺ããã®ã§ããã
ååç©ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«
âïŒâã«ã«ããã·ã¢ããããã³ïŒâïŒïŒïŒïŒïŒïŒ
âããªââã¢ã»ãã«âβââãªããã©ãã·
ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããããã³ïŒ
âïŒïŒââãã¹ããªã«âβââãªããã©ãã·
ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ãããå«ãã
ã®ãšã¹ãã«ã¯ãã€ã³ãŽã€ãã§ã®æè
«çå€ãšããŠæ
çšã§ãããšãããã»ã©éèŠãªæè
«ç掻æ§ãåãã
ããšãèªããããã
æ¬çºæã®ç°¡åãªèŠçŽ
ååç©ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«
âïŒâã«ã«ããã·ã¢ããã¯ã€ã³ãŽã€ãã§èæãªæ
è
«ç掻æ§ãåããããšãèªãããããæ¬çºæã¯ã
ã®ååç©ããã³ããé¢é£èªå°äœã®æž©è¡åç©ã«ãã
ãæªæ§è
«çæ²»çãžã®äœ¿çšã«é¢ãããæ¬çºæã«ã
ããïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒ
âã«ã«ããã·ã¢ããããã³ãã®é¢é£ãšã¹ãã«ã®æ
è
«çç¹æ§ã¯ãæž©è¡åç©ãžæŽ»æ§æåãšããŠçµæç©ç·
ééã«åºã¥ãå°ããšãããã³0.1ééïŒ
ã®æ§é ïŒ
ïŒåŒäžR1ããã³R2ã¯ïŒšåã¯C1âC18ã¢ã·ã«ã§ã
ããR3ã¯ããC1âC18ã¢ã·ã«åã¯
This application was filed on December 15, 1980.
This is a continuation in part of my pending application No. 216197, entitled Treatment of Malignant Tumors with Ribofuranosylthiazole-4-carboxamide and related compounds, and the entire disclosure of which is hereby incorporated by reference. The present invention provides a path to the treatment of malignant tumors in vivo using the compound 2-β-D-ribofuranosylthiazole-4-carboxamide and related derivatives such as esters thereof. The control of malignant tumors in humans and animals remains an unrealized goal. Over the past few decades, remarkable advances have been made in our understanding of malignancy. However, the conquest of malignant disease states has not yet been achieved. Common treatments for both humans and other useful animal species suffering from malignant tumors currently include chemotherapy by surgical removal of the tumor in the affected animal, local radiotherapy, and administration of chemotherapeutic agents to the animal. In many patients with malignant tumors, death is not due to the initial tumor, but instead due to the initial tumor metastasizing to subsequent parts of the host. If the initial tumor is detected early, it can be removed, usually by surgery, radiation or chemotherapy, or a combination thereof. However, these primary tumor metastatic communities are very difficult to detect and eliminate, and their unsuccessful treatment has become a serious medical problem. Tumors are usually classified as either benign or malignant. Malignant tumors are identified as benign by their ability to invade surrounding tissues and to spread to distant sites by metastasis. Some organs are more susceptible to metastasis than others. Included in this group are lungs;
It has a brain, liver, ovaries and adrenal glands. Furthermore, it has been suggested that surgery and radiation directed at the initial tumor may actually promote metastasis in some cases. Given the inability of current cancer therapies to inhibit malignant tumors and their metastasis, it is clear that there is a need for additional chemotherapeutic agents. In a paper entitled Synthesis and Antiviral Activity of Certain Thiazole C-Nucleosides (J.Med.Chem. 1977, Vol. 20, No. 2256), I and my collaborators reported that the compound 2-β-D-ribofuranosylthiazole-4-carboxamide and 2-(2,3,5-tri-O-acetyl-β-
Synthesis of D-ribofuranosyl) thiazole-4-carboxamide and in vitro test system of three viruses, hydatid simplex virus type 1, parainfluenza virus type 3, and 3
Preliminary antiviral activity in vitro performed using a type of rhinovirus is described. The in vitro activity of the compound 2-β-D-ribofuranosylthiazole-4-carboxamide against these three viruses was only modest. Compound 2-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)thiazole-4
- Regarding carboxamides, only mild activity was observed with simple vesicle virus type 1, but no activity was observed with parainfluenza type 3 and rhinovirus type 13. Although some marginal in vitro antiviral activity was seen, quite to the contrary, 2
-β-D-ribofuranosylthiazole-4-carboxamide and 2-(2,3,5-tri-O
-acetyl-β-D-ribofuranosyl)thiazole-4-carboxyamide The in vivo antiviral test of both was negative as judged by the number of deaths of test animals. In this in vivo study, 2-β-D-ribofuranosylthiazole-4
- The number of test animal deaths using both carboxamide and 2-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)thiazole-4-carboxamide is the same as the number of placebo control animal deaths. Compound 2-β-
D-ribofuranosylthiazole-4-carboxamide and 2-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)thiazole-4
- shows that neither of the carboxamides demonstrated useful in vivo antiviral activity. 2-β-D-ribofuranosylthiazole-4-
For the above in vitro antiviral testing of both carboxamide and 2-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)thiazole-4-carboxamide, these compounds were compared with known antiviral compounds. Ribavirin
(RIBAVIRIN) was tested against viruses with positive antiviral activity. 2-β-D
In terms of the preliminary in vitro peripheral activity of ribofuranosylthiazole-4-carboxamide against these test viruses, the spectrum of activity of 2-β-D-ribofuranosylthiazole-4-carboxamide is similar to that of the compound ribavirin. It seems likely. Ribavirin is known to be an active in vitro and in vivo antiviral agent, and is also known to exhibit no apparent antitumor activity. Furthermore, certain derivatives of ribavirin, such as its 5'-monophosphate, are also known to be inactive as antitumor compounds. 2
The preliminary in vitro antiviral activity of -β-D-ribofuranosylthiazole-4-carboxyamide was compared with that of ribavirin.
It is reasonable to assume that ribofuranosylthiazole-4-carboxamide would exhibit the same positive in vivo antiviral activity and negative antitumor activity as ribavirin. Quite contrary to this, the compound 2-β-D-ribofuranosylthiazole-4-carboxamide had no useful in vivo antiviral activity and, quite unexpectedly, showed positive antitumor activity. . Compounds 2-β-D-ribofuranosylthiazole-4-carboxamide and 2-(2,3,5
-tri-O-acetyl-β-D-ribofuranosyl)thiazole-4-carboxamide and 2
The esters thereof, including -(5-O-phosphoryl-β-D-ribofuranosyl)thiazole-4-carboxyamide, have been found to exhibit significant antitumor activity, making them useful as antitumor agents in vivo. Ta. BRIEF SUMMARY OF THE INVENTION The compound 2-β-D-ribofuranosylthiazole-4-carboxamide was found to exhibit significant antitumor activity in vivo. The present invention relates to the use of this compound and certain related derivatives for the treatment of malignancies in warm-blooded animals. According to the present invention, 2-β-D-ribofuranosylthiazole-4
- The antitumor properties of carboxamides and their related esters extend to warm-blooded animals at least and 0.1% by weight based on the total weight of the composition as active ingredients: (In the formula, R 1 and R 2 are H or C 1 -C 18 acyl, and R 3 is H, C 1 -C 18 acyl or
ãåŒã
ã§ããïŒ
ãªãååç©ããã³ççåŠäžçžå®¹ãããã®å¡©ãå«æ
ããæå¹éã®è¬å€çµæç©ãæäžããããšã«ãã€ãŠ
å©çšãããã
ãã奜ãŸãã矀ã®ååç©ã¯R1ããã³R2ãå
ã¯C1âC8ã¢ã·ã«ã§ãããR3ããC1âC8ã¢ã·ã«
åã¯and physiologically compatible salts thereof. A more preferred group of compounds is where R 1 and R 2 are H or C 1 -C 8 acyl and R 3 is H, C 1 -C 8 acyl or
ãåŒãã§ããååç©ããã³ççåŠäžçžå®¹ã
ããã®å¡©ã§ãããR1ãR2ããã³R3ã®å¥œãŸããã¢
ã·ã«åºãšããŠã¯ã¢ã»ãã«ãããããªãã«ããããª
ã«ãã€ãœãããªã«ããã³ãã³ãŸã€ã«ãç¹èšãã
ããçžå®¹ããå¡©ãšããŠã¯ã¢ã«ã«ãªéå±ããã³ã¢ã³
ã¢ããŠã åã¯çœ®æã¢ã³ã¢ããŠã å¡©ããšãã°ãããª
ãŠã ãã«ãªãŠã ããã³ã¢ã³ã¢ããŠã å¡©ãç¹èšãã
ãã
奜ãŸããã¯ãR1ããã³R2ãã§ããæR3ã
OHãC1âC8ã¢ã·ã«åã¯Compounds of the formula and physiologically compatible salts thereof. Preferred acyl groups for R 1 , R 2 and R 3 include acetyl, propionyl, butyryl, isobutyryl and benzoyl. Compatible salts include alkali metal and ammonium or substituted ammonium salts such as the sodium, potassium and ammonium salts. Preferably, when R 1 and R 2 are H, R 3 is
OH, C1 - C8 acyl or
ãåŒãã§ããããŸ
ãR1ããã³R2ãC1âC8ã¢ã·ã«ã§ããæR3ãC1â
C8ã¢ã·ã«ã§ããã®ãæãŸããã
æ¬çºæã®è¬å€çµæç©ã«ããã䜿çšã«ã¯è¬å€æ
äœ
ãå©çšãããããè¬å€æ
äœã¯é©åœãªæ¿åºŠã®æ¬çºæ
ã®æŽ»æ§æåã溶液ãããã¯æžæ¿æ¶²ãšããŠæ³šå°ã«ã
ã眹æ£æž©è¡åç©ã«æäžã§ããããã«éžæãããã®
ã奜ãŸãããæªæ§è
«çããã€å®¿äž»ãè
«çã®åãã
ã³è
«çã®éšäœã«ããã泚å°ã«ããæäžã¯éèå
ã
çèå
ãè³å
ãç®äžåã¯åŸ©è
å
泚å°ãšããã
å¥ã«ãæ¬çºæã®çµæç©ãä»ã®çµè·¯ã«ããæäžã
ãšãã°çµå£æäžãçŒããã®æäžãå±ææäžåã¯å
å€ã«ããæäžãã§ããé©åœãªè¬å€æ
äœäžã«å
¥ããŠ
補å€åããŠãããã
詳现ãªèª¬æ
æ¬çºæã«ä¿ãååç©ãååç©ïŒâβââãªã
ãã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããã
ã¯äŸïŒã«èšèŒããããã«è£œé ããã®ã奜ãŸããã
ãã®ååç©ã®ããäžã€ã®åæã¯ããã«åç
§ãšããŠ
èšèŒãããžãšãŒã»ãªãŒã°ã»ã±ã ã»ïŒJ.Org.
Chem.ïŒã第41å·»ã第2619764074å·äžã«èšèŒãã
ãŠããã
ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâ
ã«ã«ããã·ã¢ããïŒååç©ïŒïŒã®ãšã¹ãã«ãããš
ãã°ïŒâïŒïŒïŒïŒïŒïŒâããªââã¢ã»ãã«âβ
ââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ã
ãã·ã¢ããïŒååç©ïŒïŒåã¯ïŒâïŒïŒââãã¹
ããªã«âβââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«â
ïŒâã«ã«ããã·ã¢ããïŒååç©ïŒïŒã¯ãäŸïŒãã
ã³ïŒã«åã
èšèŒãããŠããããã«è£œé ããããã
ãã«ãä»ã®ãšã¹ãã«ãããšãã°ã¢ããšã¹ãã«ïŒâ
ïŒïŒââã¢ã»ãã«âβââãªããã©ãã·ã«ïŒ
ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããïŒååç©ïŒïŒã
ã¯äŸïŒã«èšèŒããåææ³ã®åŠã補é ãããã
æ¬çºæã®ä»ã®å¥œãŸããã«ã«ããã·ãšã¹ãã«ãåŸ
ãã«ã¯ãç¡æ°Žé
¢é
žãé©åœãªç¡æ°Žç©ããšãã°ç¡æ°Žã
ãããªã³é
žãç¡æ°Žé
ªé
žåã¯ç¡æ°Žå®æ¯éŠé
žã§çœ®æã
ãŠåŸããå¥ã«ãé©åœãªé
žå¡©åç©ã¯é
žç¡æ°Žç©ã«çœ®æ
ãããããšãã§ããã
ååç©ïŒã®ãšã¹ãã«ã¯çœ¹æ£å®¿äž»ã«ãããŠæ¬åå
ç©ã®å°åºïŒdeliveryïŒã«åœ¹ç«ã€ããããååç©ã®
ãšã¹ãã«ã¯ãååç©ïŒã®ç³éšåã®ïŒåãããã¯ïŒ
å以äžã®ããããã·ã«åºãšã芪ååç©ïŒãããã®
å Žã§ã®ããååŠçãããã¯é
µçŽ çåå¿ã«ããã€ã³
ãŽã€ãã§åãé¢ãåŸãé©åœãªå¯éçããããã³ã°
åºãšåå¿ãããããšã«ãã€ãŠçæããåŸãã
ããããã·ã«åºãšã®åå¿ã§ã¯ããšã¹ãã«ããšã
ã°ãå¿
ãããéå®ãããªãããã¢ã·ã«ããã³ãã¹
ããªã«ãšã¹ãã«ãèãããããã¢ã·ã«åºã¯çŽé
ç¶ãåæç¶ã眮æãæªé£œåã飜ååã¯è³éŠæé
žã
ãšãã°ãå¿
ãããéå®ãããªãããé
¢é
žãããªã
ã«ãªãé
¢é
žãããããªã³é
žãïœâé
ªé
žãã€ãœé
ª
é
žãåèé
žãã«ããã³é
žããã©ã«ãŽã³é
žããšãã³
ãé
žãã«ããªã«é
žãä¹³é
žãã¢ã¯ãªã«é
žããããã«
ã®ã«é
žããã«ããã«é
žãå®æ¯éŠé
žããã¿ãŒã«é
žã
ãµãªãã«é
žãã±ã€ç®é
žããã³ããããšé
žãããªã
矀ããéžæãããããšãã§ãããããããã¹ããª
ã«åºãéžæãããšããã¹ããªã«ãšã¹ãã«ãéé¢é
ž
ãšããŠåã¯å¡©ãšããŠçæããåŸãããã¹ããªã«ãš
ã¹ãã«ã®ãã¹ããšãŒãéšåã®çžå®¹ããå¡©ã¯ãå¿
ã
ããéå®ãããªãããã¢ã«ã«ãªããã³ã¢ã«ã«ãªå
é¡ãããšãã°ãããªãŠã ãã«ãªãŠã ãã«ã«ã·ãŠ
ã ããã°ãã·ãŠã ããªããŠã ãã¢ã³ã¢ããŠã ãã
ã³çœ®æã¢ã³ã¢ããŠã ãããªã¢ã«ãã«ã¢ã³ã¢ããŠ
ã ããžã¢ã«ãã«ã¢ã³ã¢ããŠã ãã¢ã«ãã«ã¢ã³ã¢ã
ãŠã ãããšãã°ããªãšãã«ã¢ã³ã¢ããŠã ãããªã¡
ãã«ã¢ã³ã¢ããŠã ããžãšãã«ã¢ã³ã¢ããŠã ããªã¯
ãã«ã¢ã³ã¢ããŠã ãã»ãã«ããªã¡ãã«ã¢ã³ã¢ããŠ
ã ããã³ã»ãã«ããªãžãŠã ãããªã矀ããéžæã
ãåŸãã
奜ãŸãã圢æ
ã®æ¬çºæã®ãšã¹ãã«ãšããŠãåå
ç©ïŒïŒïŒããã³ïŒãæããããããããã«å ã
ãŠãä»ã®ããªââã¢ã·ã«ãšã¹ãã«ããšãã°2â²ïŒ
3â²ïŒ5â²âããªââãã³ãŸã€ã«ãæãããããã
ãã«ãä»ã®ã¢ããšã¹ãã«ããšãã°5â²ââãã³ãŸ
ã€ã«ãæãããããéåžžãã«ã«ããã·ãšã¹ãã«ãš
ããŠå¥œãŸãããšã¹ãã«ã¯C1âC18ã¢ã·ã«ãå«ãã
ãã奜ãŸãã矀ã¯C1âC8ã¢ã·ã«ãå«ãããã¹ã
ãªã«ãšã¹ãã«ãå©çšããæã«ã¯ããã¹ããšãŒãåº
ãå¡©ãšããŠå¥œãŸããã¯ãããªãŠã å¡©ãããã¯ä»ã®
ã¢ã«ã«ãªéå±å¡©åã¯ã¢ã³ã¢ããŠã ãšããŠçæãã
ã®ã奜ãŸããã
æ¬æã®äŸäžã«ç€ºããåŠããååç©ïŒã®ãšã¹ãã«
圢ã¯çœ¹æ£å®¿äž»ã«ãããŠã¯çœ¹æ£éšãžã®æ¬ååç©ã®å°
åºã«æçšã§ãããäŸã«ç€ºããåŠããããªâã¢ã»ã
ã«ãšã¹ãã«ïŒååç©ïŒïŒã眹æ£å®¿äž»ãžè
¹è
å
泚å°
ãããšæå¹ãªæè
«çå€ã§ããããšãããããäžèš
ããªã¢ã»ãã«ååç©ããã³ååç©ïŒã®ããããã®
ä»ã®ã¢ã·ã«ãšã¹ãã«ã¯ãããçç©åŠçæµäœããšã
ã°èã®é
žç°å¢åã¯ã€ã³ãŽã€ãã§ãšã¹ãã«ãé
µçŽ ã«
ãã€ãŠåãé¢ããŠååç©ïŒã«ããããšãã§ããã
ããªé©åœãªé
µçŽ ãå«ãç°å¢äžã§å æ°Žå解ãããå
åç©ïŒã«ãªããšæããããç§ã¯çè«ã«çžãããã
ãšãæãŸãªããããããååç©ïŒã®ãã¹ããªã«ãš
ã¹ãã«ãããšãã°5â²âãã¹ããšãŒãããçšãã
ãšãä»ã®ã€ã³ãŽã€ãã§ååšããé
µçŽ ããŸãããã¹
ããšãŒããé©åœã«é
µçŽ ã«ãã€ãŠåãé¢ããŠãã®å Ž
ã§ååç©ïŒãå°åºãããšæããäŸã«ç€ºããåŠãå
åç©ïŒã®ãã¹ããªã«ãšã¹ãã«ã§ããååç©ïŒã眹
æ£å®¿äž»ã«æ³šå°ãããšãæå¹ãªæè
«çå€ã§ããããš
ã瀺ããããããã§ã¯ãã®æŽ»æ§ã5â²âãã¹ããšãŒ
ããšããŠè¡šããããã®ãåã¯ãããé
µçŽ ã«ãã€ãŠ
åãé¢ãããŠååç©ïŒã«ãªã€ãŠããã®ãã©ããã
ãããªããããã«ãååç©ïŒã¯ãã®å Žã§ä»ã®é
µçŽ
åå¿ã«ããååç©ïŒã«é²ãããšãå¯èœã§ãããã
ããã«ããŠããååç©ïŒããã³ååç©ïŒã®äž¡æ¹ãš
ãäŸã«ãã€ãŠç€ºãããåŠãæå¹ãªã€ã³ãŽã€ãæè
«
çå€ã§ããããšããããã
æ¬çºæãå®æœããã«ã¯ãååç©ïŒåã¯ãã®éžæ
ããããšã¹ãã«åœ¢ãé©åœãªè¬å€æ
äœãšæ··åããã®
ãé©åœã§ããããã®è¬å€æ
äœã¯ç¡èæ°Žã®ããã«å
äžã§ãã€ãŠãããããåã¯é©åœã«æš¡å£ããããç
ç©åŠçç°å¢ãã€ããã®ã«é©åœãªè¬å€ãå«ãè€åæ
äœãããªãã¡ãéèå
ãçèå
ãããã¯ãã®ä»ã®
泚å°ã«é©ãããããªPHããã³å¡©èª¿æŽæº¶æ¶²ãã§ãã€
ãŠãããã
é©ããè¬å€æ
äœã®éžæã«ã¯ãè
«çã®åãè
«çã®
éšäœããã³å®¿äž»ã®å¥åº·ç¶æ
ããã³å¹Žä»€ãèããã
ããã«ãååç©ïŒã®ãšã¹ãã«åœ¢ãçšããå Žåã«
ã¯ããšã¹ãã«ã®ååŠçåå¿æ§ããèæ
®ããããã
ããŠãã«ã«ããã·ã¢ã·ã«ãšã¹ãã«ãé©åœãªéâé
ž
æ§åªè³ªäžã«æžæ¿åã¯æº¶ããã®ã奜ãŸããããã¹ã
ãªã«ãšã¹ãã«ãé©åœãªç·©è¡æ¶²ã®ååšäžã«ãåã¯äž
èšã®åŠãå¡©ãšããŠçšããã®ãé©åœã§ããã
ååç©ïŒåã¯æ¬çºæã®ããããä»ã®ååç©ãã
ååç©ïŒåã¯ãã®èªå°äœããã®æ
äœäžã«é©åœã«æº¶
解ãããããªé©åœãªè¬å€æ
äœãšæ··åããã®ã奜ãŸ
ãããããããªããå¥ã«ãæžæ¿æ¶²ãä¹³æ¿æ¶²ããã³
æ¬çºæã®ååç©ã®ä»ã®åŠæ¹ããæ瀺ãããå Žåã«
ã¯äœ¿çšããããšãã§ãããè¬å€æ
äœã¯ãããã«å«
ãŸããå¯æº¶ååã¯æžæ¿åå€ã«å ããŠãããã«é©åœ
ãªåžéå€ãç·©è¡æ¶²ãè¡šé¢æŽ»æ§å€ããã³è¬å€æ
äœäž
ã®ä»£è¡šçã«çšããããä»ã®é¡äŒŒè¬å€ããå«ããã
ãããªãããè¬å€æ
äœã®å
šäœã®çµæã¯å°åºéšäœã
掻æ§æåã®æ¿åºŠããã³è£œè¬å·¥æ¥ã§æšæºãšãªãä»ã®
ãã©ã¡ãŒã¿ãŒãšäºãã«çžå®¹ããããéžæããå¿
èŠ
ãããã
ååç©ïŒåã¯æ¬çºæã®ä»ã®ååç©ããç·çµæç©
ã®å°ããšã0.1ééïŒ
ã®æ¿åºŠã§ååšããè¬å€æ
äœ
ãšé©åœã«æ··åããããããè¬å€æ
äœäžã«ç·çµæç©
ã®ããã10ãªããããã90ééïŒ
ã®æ¿åºŠã§ååšã
ãã®ã奜ãŸããã
æå¹éã®ååç©ïŒåã¯ãã®ä»ã®æ¬çºæã®ååç©
ã¯ä»£è¡šçã«ã¯ãïŒæ¥åœã被åŠçœ®æž©è¡åç©ã®ç·äœé
Kgã«ã€ãããã2.5mgãªããããã200mgã®ç¯å²ã«
ãããããã®ç¯å²ã¯12.5mgïŒKgãªããããã³100
mgïŒKgã§ããã®ã奜ãŸãããããã«ãã奜ãŸãã
ç¯å²ã¯ããã15mgïŒKgãªããããã50mgïŒKgã§ã
ããäžèšã®ä»ã®å åãšåæ§ã«ã眹æ£åç©ã®åŠçœ®ã«
çšããååç©ã®éã¯ãè
«çã®åãè
«çéšäœãåå
ç©ã®æäžåœ¢æ
ããã³å®¿äž»ã®èº«äœã®å€§ãããšç¶æ
ã®
ãããªãã©ã¡ãŒã¿ãŒãèšç®ã«å
¥ããå¿
èŠãããã
ãšã«ãããå®éã®éã¯ååŠçæ³äžæå¹éã®è¬å€ã
宿䞻ã«å¯ŸããŠé©åéæäŸããã®ã«ååã§ãªããŠã¯
ãªããããããŠçç·Žããåœæ¥è
ã«ãšã€ãŠã¯ããã«
èšèŒããããšã決å®ããã®ã¯å®¹æã§ããã
å°ããšãïŒã€ã®ç 究ã§ã¯ãæ¬çºæã®ååç©ïŒã
2000mgïŒKgã§ã®æäžéã§è
«çããã€åç©ãžæ³šå°ã
ããšãããæ¯æ§è©Šéšæ¥ã«ã¯ååç©ïŒã®æ¯æ§ã«ãã€
ãŠæ»äº¡ããåç©ã¯äžå¹ãããªãã€ããæªæ§è
«çã«
ããæªæã«ãããšèšºæãã宿䞻ã«ãããŠãããã
ãäœããã®æ²»çã®å¯èœæ§ãæªæã«ãã宿䞻ã«ãã
ãšãããä»æ¥ã®çååŠçæ³ã§éåžžè¡ãããŠããã
ãã«æ¯æ§ã®ç¯å²ãè¶ããéå°éãæ瀺ãããŠãã
ãã
次ã®äŸèšŒæ¥çã«çšããããäŸã«ãããåŠããè
«
çãæãã宿䞻ã«ã¯æ瀺ãããè©Šéšååç©ã¯ïŒæ¥
ïŒåæäžãããèšåºç¶æ
ã«ãããååç©ïŒåã¯æ¬
çºæã®ããããä»ã®ååç©ã®äžæ¥æäžéã¯äŸãšå
ãæ§ã«äžããŠãããïŒãããäžæ¥æäžéãããã€
ãã®åäœæäžéã«åããå
šäœã§äžæ¥æäžéã«ãªã
ããã«äžããããšãã§ãããããããŠãããšã
ã°ã50mgïŒKgæäžã¬ãã«ã§ã¯æ£è
ã«ïŒæ¥ïŒå12.5
mgïŒKgã®æäžéãäžããŠãããã
æž©è¡åç©ã®æªæ§è
«çãæå¶ããã®ã«çšãããã
çµæç©ã¯ãååç©ïŒåã¯ããããä»ã®æ¬çºæã®å
åç©ãè¬çåŠäžçžå®¹ãã溶åªãžæ·»å ãã次ã«æ®ºè
ãããã€é©åœãªå¯å°ãåŸããã€ã¢ã«ãžç¥ãããŠã
ãæ¿åºŠã«ãŠå
å¡«ããããšã«ãã€ãŠè£œé ããã®ãé©
åœã§ãããé©åœãªæäžéã®ååç©ã次ã«ãã€ã¢ã«
ããåãåºããŠå®¿äž»ãžæ³šå°ã«ããæäžããã
äŸ ïŒ
ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâ
ã«ã«ããã·ã¢ãããååç©ïŒ
ãšãã«ïŒâïŒïŒïŒïŒïŒïŒâããªââãã³ãŸã€
ã«âβââãªããã©ãã·ã«ïŒâãã¢ãŸãŒã«âïŒ
âã«ã«ããã·ã¢ããããããã«åç
§ãšããŠèšèŒã
ãŠã¹ãªãã¹ããïŒSrivastovaïŒçããžãšãŒïŒã¡
ãïŒã±ã ïŒïŒJ.Med.Chem.ïŒã1977ã第20å·»ã第
2256å·ã«ãŠè£œé ããåŠãå©çšãããã¡ã¿ããŒã«
ïŒ15mlïŒäžã®ãšãã«ïŒâïŒïŒïŒïŒïŒïŒâããªââ
ãã³ãžã«âβââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«
âïŒâã«ã«ããã·ã¢ããïŒ5.0ïœã8.31ããªã¢ã«ïŒ
ã®æ¿çž®æº¶æ¶²ããã¡ã¿ããŒã«æ§ã¢ã³ã¢ãã¢ïŒïŒâã§
飜åã100mlïŒãšå§åãã³äžã§å®€æž©ã«ãŠïŒæ¥éæ¹
æããã溶åªãèžçºãããæ®çç©ãé
¢é
žãšãã«äž
ã«è©°ããã·ãªã«ã²ã«ïŒ100ïœïŒã®ã«ã©ã ïŒ2.5Ã35
cmïŒãéããŠã¯ãããã°ã©ãã€ãŒã«ãããã溶åª
ç³»ïŒé
¢é
žãšãã«âïŒâãããããŒã«âæ°ŽãïŒïŒ
ïŒïŒïŒïŒïŒ¶ïŒïŒ¶ïŒæäžå±€ïŒã§ã«ã©ã ã溶åºãããš
æ©ã移åããå®æ¯éŠé
žã¡ãã«ãšãã³ãºã¢ãããå
ãã倧éšåã®ãã€ãããšç§»åããUVããã³ç³â
ãã©ã¹ïŒsugarâpositiveïŒåç»ãéãããã€æº¶
åªãæžå§äžã«èžçºããããããããŠåŸãããæ®ç
ç©ïŒã·ãããç¶ïŒã¯ãšã¿ããŒã«âé
¢é
žãšãã«ãã
容æã«æ¶åºããŠ1.6ïœïŒ74ïŒ
ïŒã®çŽç²ãªçæç©ã
ååç©ïŒïŒm.p.144â145âïŒãαã25 pâ14.3ãïŒC1ã
DMFïŒïŒUVãnaxPH1237nmïŒ8640ïŒïŒUVãnaxPH
11238nmïŒ8100ïŒïŒ1HNMRïŒMc2SOâd6ïŒÎŽ7.5â
7.8ãïŒbrïŒãïŒãCONH2ã1HNMRïŒMc2SOâd6
âD2OïŒÎŽ4.99ïŒïœãïŒãâ5H2ãH1â²ïŒã8.25
ïŒïŒ³ãïŒãH5ïŒãåæïŒC9H12N2O5SïŒïŒ£ãã
ãããæäŸããã
äŸ ïŒ
ïŒâïŒïŒïŒïŒïŒïŒâããªââã¢ã»ãã«âβâ
âãªããã©ãã·ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ã
ãã·ã¢ãããååç©ïŒ
ç¡æ°Žé
¢é
žïŒ2.0mlïŒããç¡æ°Žããªãžã³ïŒ16mlïŒ
äžã®ååç©ïŒïŒ1.04ïœãïŒããªã¢ã«ïŒã®æ°·å·æº¶æ¶²
ãžæ·»å ãããã®åå¿æº¶æ¶²ã宀枩ã§17æéæ¹æã
ãã溶åªãæžå§äžã«èžçºãããæ®çç©ãé
¢é
žãšã
ã«äžã«æº¶ããããã®æº¶æ¶²ãæ°ŽæŽããŠä¹Ÿç¥ããã
ïŒMgSO4ïŒãé
¢é
žãšãã«éšãæžå§äžã«èžçºããã
ããããŠåŸãããæ®çç©ãæ°Žããæ¶åºãããŠ1.4
ïœïŒ90ïŒ
ïŒã®ååç©ïŒãçœè²éç¶ç©ãšããŠåŸãïŒ
m.p.103âïŒ1HNMRïŒCDCl3ïŒ2.1ïŒ3SãïŒãããª
ââã¢ã»ãã«ïŒã6.2ããã³7.15ãïŒbrïŒã®å¯Ÿã
ïŒãCONH2ãã8.2ïŒïŒ³ãïŒãH5ïŒãåæã
ïŒC15H18N2O8SïŒïŒ£ãããã
äŸ ïŒ
ïŒâïŒïŒââãã¹ããªã«âβââãªããã©
ãã·ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ãã
ïŒïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒ
âã«ã«ããã·ã¢ãã5â²âãã¹ããšãŒãïŒãåå
ç©ïŒ
æ°ŽïŒ151mgã8.4ããªã¢ã«ïŒã泚ææ·±ããæ°ãã«
èžçããå¡©åãã¹ããªã«ïŒ2.0ïœã13.2ããªã¢
ã«ïŒãããªãžã³ïŒ1.21ïœã14.4ããªã¢ã«ïŒããã³
ã¢ã»ããããªã«ïŒ2.3ïœã56.7ããªã¢ã«ïŒãããª
ã溶液ïŒæ¹æããªããïŒâã«ä¿ã€ïŒãžæ·»å ããã
ïŒâβââãªããã©ãã·ã«ãã¢ãŸãŒã«âïŒâã«
ã«ããã·ã¢ããïŒååç©ïŒïŒïŒP2O5ã§ä¹Ÿç¥ãããŠ
ç²æ«ç¶ã«ãããã®ã800mgã3.0ããªã¢ã«ïŒããã®
溶液ãžæ·»å ããåå¿æ··åç©ãç¶ç¶ããŠïŒæéïŒâ
ã«ãŠæ¹æãããåå¿æ··åç©ãæ°·æ°ŽïŒããã50mlïŒ
äžãžæ³šããPHã2Næ°Žé
žåãããªãŠã ã§2.0ã«èª¿æŽ
ããããã®æº¶æ¶²ã掻æ§çïŒ20ïœïŒã®ã«ã©ã ã«ã
ãããã®ã«ã©ã ã溶åºæ¶²ãå¡©ãå«ãŸãªããªããŸã§
培åºçã«æ°ŽæŽãããã«ã©ã ããšã¿ããŒã«âæ°Žâæ¿
æ°Žé
žåã¢ã³ã¢ããŠã ïŒ10ïŒ10ïŒïŒïŒæº¶æ¶²ã§æº¶åº
ããåç»ïŒå25mlïŒãããéããã粟補ïŒtlcã
ã·ãªã«ã²ã«ãã¢ã»ããããªã«â0.1Nå¡©åã¢ã³ã¢
ããŠã ïŒïŒïŒïŒïŒïŒãã¯ã¬ãªããïŒååç©ïŒïŒã
å«ãåç»ãããéããæžå§äžã«èžçºä¹Ÿç¥ãããã
ç¡æ°Žæ®çç©ãæ°Žäžã«æº¶ãããããŠãšãã¯ã¹
ïŒdowexïŒ50WâX8ïŒ20â50ã¡ãã·ãŠãH+åã15
mlïŒã«ã©ã ãéããã«ã©ã ãæ°ŽæŽãããã¯ã¬ãªã
ããå«æããåç»ãéããã溶液ãæ¿çž®ããŠå°é
ïŒïŒmlïŒã«ããããŠãšãã¯ã¹ïŒDowexïŒ50Wâ
X8ïŒ20â50ã¡ãã·ãŠãNa+圢ã15mlïŒã®ã«ã©ã ã
éãããã®ã«ã©ã ãæ°ŽæŽããããã¯ã¬ãªãããå«
ãåç»ãåçµä¹Ÿç¥ãããæ®çç©ããšã¿ããŒã«ã§ç²
ç ãããéã«ãã€ãŠéãããã€ä¹Ÿç¥ïŒP2O5ïŒã
ããŠ560mgïŒ47ïŒ
ïŒã®ååç©ïŒããäžãããªãŠã
äºæ°Žåç©ãšããŠçµæ¶åœ¢ã§åŸãã
åæãC9H12N2O8PSNaã»2H2OãšããŠã®
èšç®å€ïŒïŒ£ã27.13ïŒïŒšã4.04ïŒïŒ®ã
7.04ïŒ
ã7.78ïŒïŒ³ã8.05ã
å®æž¬å€ïŒïŒ£ã27.42ïŒïŒšã3.87ïŒïŒ®ã7.07ïŒ
ã8.03ïŒïŒ³ã8.41ã
äŸ ïŒ
ïŒâïŒïŒââã¢ã»ãã«âβââãªããã©ã
ã·ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ãããå
åç©ïŒ
ç¡æ°Žããªãžã³ïŒ20mlïŒäžã®ïŒâïŒïŒïŒïŒââ
ã€ãœããããªãã³âβââãªããã©ãã·ã«ïŒã
ã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããïŒ1.5ïœãïŒã
ãªã¢ã«ïŒïŒããšã«ãã¹ïŒFuertesïŒçããžãšãŒã»ãª
ãŒã°ã»ã±ã ã»ïŒJ.Org.Chem.ïŒã第41å·»ã第26å·ã
1976幎ã4074ã®åŠã補é ïŒã®æº¶æ¶²ã氷氎济äžã§å·
åŽãããã€ç¡æ°Žé
¢é
žïŒ2.5mlïŒããã€ãããšæ¹æ
ããªããæ·»å ãããåå¿æº¶æ¶²ã宀枩ãŸã§å æž©ãã
æ¹æã15æéç¶ããã溶åªãæžå§äžã«èžçºããã
æ®çç©ãé
¢é
žãšãã«äžã«æº¶ããããã€æ°ŽæŽããã
é
¢é
žãšãã«éšåãæžå§äžã«èžçºãããæ®çç©ã80
ïŒ
é
¢é
žïŒ25mlïŒäžã®æº¶ããããã®æº¶æ¶²ãèžæ°æµŽäž
ã§30åéå ç±ãããã€æº¶åªãæžå§äžã«èžçºãã
ããæ®çç©ãé
¢é
žãšãã«äžã«æº¶ãããæ°Žã§äžåæŽ
æµãããã€MgSO4ã§ä¹Ÿç¥ããããé
¢é
žãšãã«éš
åãèžçºãããç²çæç©ãã·ãªã«ã²ã«ïŒ100ïœã
ã¯ãããã«ã ã«è©°ããïŒã«ã©ã ãéãããã€ã¯ã
ããã«ã äžã®20ïŒ
ïŒïŒ¶ïŒïŒ¶ïŒé
¢é
žãšãã«ã§æº¶åºã
ãããã¯ã¬ãªãããæããåç»ã貯çãããã€èž
çºãããŠ1.05ïœïŒ70ïŒ
ïŒã®ååç©ïŒãåŸãã
ïŒC11H14N2O6SïŒã
ååç©ïŒããã³æ¬çºæã®ä»ã®äŸèšŒååç©ã®å®èšŒ
äŸãšããŠã以äžã®äŸïŒãªãã12ãæãããããã
ã®äŸã§ã¯ãååç©ã®å¹åãããçš®ã®æªæ§è
«çã«å¯Ÿ
ããæšæºè©ŠéšãçšããŠèšŒæããããããã®å®èšŒäŸ
ã§çšããè©Šéšã¯åœéçç 究æãçæ²»çéšéãéçº
æ²»çèšç»ã«ããæå°ãåããŠè¡ã€ããã®ã§ããã
æ¬è©Šéšã¯ãããã®æšæºåå®æžïŒprotocolïŒããã³
æ¹æ³ãçšãããã®æ©é¢ã«ããç£ç£ãåããŠè¡ãã
ãããã¹ãŠã®è©Šéšã¯ãããã®åå®æžã«åŸãããŸã
ãã¹ãŠã®è©Šéšã¯ãããã®åå®æžã«ãã€ãŠæ瀺ãã
ãå€å®åºæºã®ããšã«è©äŸ¡ãããã次ã®ä»£è¡šäŸã¯åœ
éçç 究æã®ã¹ã¯ãªãŒãã³ã°è
«çæ¹åŒã«ãããŠæ¬
çºæã®äŸèšŒååç©ã瀺ãã確ããªæŽ»æ§ãäŸèšŒãã
ãã®ã§ããã
以äžã®äŸã«ãããŠãç¥åIPã¯è
¹è
å
ãè¡šããã
ãŸãIVã¯éèå
ãè¡šãããçåæéã®å¹³åãã
ã³äžå€®å€ã¯åœéçç 究æãçæ²»çéšéãéçºæ²»ç
èšç»ãã¹ã¯ãªãŒãã³ã°ããŒã¿ãŒèŠ§ã®ææ14ïŒæ¹èš
ïŒïŒïŒïŒïŒã«ãŠèšç®ããããé©åœãªæ¹èšãå«ãéã¹ã¯
ãªãŒãã³ã°ããŒã¿ãŒèŠ§ã®å
容ãããã«åç
§ãšããŠ
èšèŒããã
以äžã®å®èšŒäŸã§ã¯ãè¬å€ã«æ
äœãšããŠçšãã賊
圢å€ããæ¬è©Šéšã®ãããªã賊圢äŸã«ãã圱é¿ãã
é€ãããã«è¬å€åŠçœ®åç©ã«çšãã賊圢å€ãšåãã¬
ãã«ã«ãŠã察ç
§åç©ã«æ³šå°ããïŒãã®äžã®ãããª
ãè¬å€ããé€ãïŒã
äŸ ïŒ
åçããã掻æ§ã®ææšãšããŠãæ¬çºæã®ååç©
ïŒãâ1210ãªã³ãç·çœè¡ç
ã«å¯Ÿããã€ã³ãŽã€ã
ã§ã®CD2F1éããŠã¹ãè©Šéšçš®ãšããŠçšããŠã¹ã¯ãª
ãŒãã³ã°ãããéžæãããå¹åã®ãã©ã¡ãŒã¿ãŒã¯
è¬å€ãåŠçœ®ããåç©å¯Ÿé©åœãªå¯Ÿç
§çŸ€åç©ã®çåæ
éã®äžå€®å€ã«åºã¥ããè¬å€åŠçœ®åç©ããã³å¯Ÿç
§çŸ€
åç©ã®åæ¹ã«å¯Ÿããè
¹æ°Žã«ïŒ¬â1210ãªã³ãæ§çœè¡
ç
ã®105ã·ãŒãïŒseedïŒçŽ°èãIPæ¥çš®ããã
è
«çãæ¥çš®ããŠããïŒæ¥åŸã«ãè¬å€çŸ€ã®åç©ã
次ã®ç¬¬ïŒè¡šã«èšèŒããåŠãæäžéã¬ãã«ã«ãŠãå
åç©ïŒã®åŠçœ®çµ±æ²»äžã«ãããè¬å€åŠçœ®çŸ€ã®åç©ã«
ã¯ïŒæ¥ïŒåïŒæ¥éèšèŒæäžéã«ãŠæ°Žã§é©åœã«åžé
ããè©Šéšååç©ãIP泚å°ã«ãã€ãŠæ¥çš®ããã
è¬å€æ¯æ§ã®ææšãšããŠïŒæ¥ãéžæããããã®äŸ
ã§ã¯ããã¹ãŠã®è¬å€åŠçœ®åç©ãïŒæ¥ã®éçåããŠ
ãããïŒæ¥åŸã®è¬å€åŠçœ®åç©ã®æ»ã¯ãããããã
è
«çã«ããæ»ã§ãããè¬å€æ¯æ§ã«ãããã®ã§ã¯ãª
ãã
察ç
§çŸ€ã®æ»äº¡æ¥ã®äžå€®å€ã¯8.5æ¥ã§ãã€ããäž
ã®ç¬¬ïŒè¡šã«ç€ºããåŠããè¬å€åŠçœ®çŸ€ã®æ»äº¡æ¥ã®äž
倮å€ã¯ããããã¬ãã«ã®åŠçœ®è¬å€ã«ãããŠã察ç
§
矀ããé·ãããŸã50mgïŒKgïŒè¬å€éïŒè©Šéšåç©ã®
äœéïŒä»¥äžã§ã¯æããã«ããé·ãã€ããäžã®ç¬¬ïŒ
è¡šã«ç€ºããçµæã¯ããã®åéæ€å®ã«ãããŠæ¬è¬å€
ãéœæ§ã®æŽ»æ§ãåããããšã瀺ããŠããã
125ïŒ
以äžã®è¬å€åŠçœ®åç©ïŒå¯Ÿç
§åç©ã®ïŒ
ãéœ
æ§ã®è¬å€æŽ»æ§ãšã¿ãªãã[Formula] and when R 1 and R 2 are C 1 - C 8 acyl, R 3 is C 1 -
Preferably it is a C 8 acyl. For use in the pharmaceutical compositions of the present invention, a pharmaceutical carrier is utilized, which is selected so that an appropriate concentration of the active ingredient of the present invention can be administered by injection as a solution or suspension to a diseased warm-blooded animal. It is preferable to Depending on the host with the malignant tumor, the type of tumor, and the location of the tumor, administration by injection may be intravenous,
Intramuscular, intracerebral, subcutaneous, or intracavitary injection. Alternatively, the compositions of the invention may be formulated in suitable pharmaceutical carriers for administration by other routes, such as oral, ocular, topical or suppository administration. Detailed Description Compound according to the present invention, compound 2-β-D-ribofuranosylthiazole-4-carboxamide,
is preferably prepared as described in Example 1.
An alternative synthesis of this compound is provided by J.Org.
Chem.), Volume 41, No. 2619764074. 2-β-D-ribofuranosylthiazole-4-
Esters of carboxamides (compound 1), such as 2-(2,3,5-tri-O-acetyl-β
-D-ribofuranosyl)thiazole-4-carboxamide (compound 2) or 2-(5-O-phosphoryl-β-D-ribofuranosyl)thiazole-
4-Carboxamide (Compound 3) is prepared as described in Examples 2 and 3, respectively. Additionally, other esters, such as the monoester 2-
(5-O-acetyl-β-D-ribofuranosyl)
Thiazole-4-carboxamide (compound 4),
is prepared as in the synthesis described in Example 4. Other preferred carboxyesters of the invention are obtained by replacing acetic anhydride with a suitable anhydride such as propionic anhydride, butyric anhydride or benzoic anhydride. Alternatively, suitable acid chlorides can be replaced by acid anhydrides. Esters of Compound 1 serve for delivery of the compound in the affected host. Esters of such compounds include one or two sugar moieties of compound 1.
may be generated by reacting one or more hydroxyl groups with a suitable reversible blocking group that can be cleaved from the parent compound 1 in vivo by some in situ chemical or enzymatic reaction. For reaction with hydroxyl groups, esters such as, but not necessarily limited to, acyl and phosphoryl esters are contemplated. Acyl groups are linear, branched, substituted, unsaturated, saturated or aromatic acids such as, but not necessarily limited to, acetic acid, trifluoroacetic acid, propionic acid, n-butyric acid, isobutyric acid, valeric acid, caproic acid, pelargonic acid, enanthic acid, caprylic acid, lactic acid, acrylic acid, propargyl acid, palmitic acid, benzoic acid, phthalic acid,
It can be selected from the group consisting of salicylic acid, cinnamic acid and naphthoic acid. If a phosphoryl group is selected, a phosphoryl ester can be produced as the free acid or as a salt. Compatible salts of the phosphate moiety of the phosphoryl ester include, but are not necessarily limited to, alkali and alkaline earth salts such as sodium, potassium, calcium, magnesium, lithium, ammonium and substituted ammonium, trialkylammonium, dialkylammonium, alkylammonium, e.g. It may be selected from the group consisting of triethylammonium, trimethylammonium, diethylammonium, octylammonium, cetyltrimethylammonium and cetylpyridium. Preferred forms of the esters of the invention include compounds 2, 3 and 4. In addition to these, other tri-O-acyl esters such as 2',
3',5'-tri-O-benzoyl is mentioned. Furthermore, other monoesters such as 5'-O-benzoyl may also be mentioned. Typically, preferred carboxyesters include C1 - C18 acyl.
A more preferred group includes C1 - C8 acyl. When phosphoryl esters are utilized, it is preferred to form the phosphate group as a salt, preferably as a sodium salt or other alkali metal salt or ammonium salt. As shown in the examples herein, the ester form of Compound 1 is useful in diseased hosts to deliver the compound to the affected area. As shown in the examples, tri-acetyl ester (compound 2) is shown to be an effective antitumor agent when injected intraperitoneally into affected hosts. The above triacetyl compounds and other acyl esters of any of Compound 1 may be prepared by a suitable enzyme such that the ester can be enzymatically cleaved to Compound 1 in the acidic environment of a biological fluid such as the stomach or in vivo. It is thought that Compound 1 is hydrolyzed in an environment containing I do not wish to be bound by theory, but if we use a phosphoryl ester of compound 1, e.g. I think we will derive compound 1 in situ. As shown in the examples, Compound 3, the phosphoryl ester of Compound 1, is shown to be an effective antitumor agent when injected into a diseased host. It is not known here whether the activity is expressed as the 5'-phosphate or whether it is cleaved off by the enzyme to form compound 1. Furthermore, compound 1 can also proceed to compound 3 by other enzymatic reactions in situ. In any case, both Compound 1 and Compound 3 are found to be effective in vivo antitumor agents as shown by the examples. In the practice of this invention, it is appropriate to mix Compound 1, or the selected ester form thereof, with a suitable pharmaceutical carrier, which may be alone, such as sterile water, or It may also be a complex carrier containing appropriate agents to appropriately mimic a certain biological environment, ie, a PH and salt adjusted solution suitable for intravenous, intramuscular or other injection. Selection of a suitable drug carrier takes into account the type of tumor, the site of the tumor, and the health and age of the host.
Furthermore, when using the ester form of Compound 1, the chemical reactivity of the ester is also taken into account. Thus, it is preferred to suspend or dissolve the carboxyacyl ester in a suitable non-acidic medium. It is also suitable to use phosphoryl esters in the presence of suitable buffers or as salts as described above. Compound 1 or any other compound of the invention,
Preferably, Compound 1 or a derivative thereof is mixed with a suitable pharmaceutical carrier such that the compound is suitably dissolved in the carrier. Alternatively, however, suspensions, emulsions and other formulations of the compounds of the invention can also be used, if indicated. Pharmaceutical carriers, in addition to the solubilizing or suspending agents included therein, also include suitable diluents, buffers, surfactants and other similar agents typically employed in pharmaceutical carriers. However, the overall composition of the drug carrier is
It must be selected in a manner that is compatible with the concentration of active ingredient and other parameters standard in the pharmaceutical industry. Compound 1 or other compounds of the invention are suitably mixed with the pharmaceutical carrier present in a concentration of at least 0.1% by weight of the total composition. Preferably, it is present in the pharmaceutical carrier at a concentration of about 10 to about 90% by weight of the total composition. An effective amount of Compound 1 or other compounds of the invention will typically be applied per day to the total body weight of the warm-blooded animal being treated.
Ranging from approximately 2.5mg to approximately 200mg per kg. This range is from 12.5mg/Kg to 100
Preferably it is mg/Kg. An even more preferred range is approximately 15 mg/Kg to approximately 50 mg/Kg. As with the other factors mentioned above, the amount of compound used to treat an affected animal must take into account parameters such as tumor type, tumor site, compound administration mode, and host body size and condition. .
In any event, the actual amount must be sufficient to provide an adequate chemotherapeutically effective amount of the drug to the host, and is within the skill of the art in determining what is described herein. is easy. In at least one study, compound 1 of the invention was
When injected into tumor-bearing animals at a dose of 2000 mg/Kg, no animals died due to Compound 1 toxicity on the day of the toxicity test. Even in a host diagnosed with an undiagnosed disease caused by a malignant tumor, if there is any possibility of cure in the undiagnosed host, as is commonly done in today's cancer chemotherapy, it is beyond the scope of toxicity. Excess amounts may be indicated. As in the following illustrative example, hosts with tumors are administered the indicated test compound once daily. Depending on the clinical situation, the daily dosage of Compound 1 or any other compound of the invention may be given as in the example; however, the daily dosage may be divided into several unit doses and the total daily dosage It can also be given in dosages. Thus, for example, at the 50 mg/Kg dosage level, patients would receive 12.5
Doses of mg/Kg may be given. Compositions used to inhibit malignant tumors in warm-blooded animals are prepared by adding Compound 1 or any other compound of the invention to a pharmacologically compatible solvent, followed by sterilization and appropriate encapsulation. Suitably, the preparation is carried out by filling known concentrations into vials to be obtained. The appropriate dose of compound is then removed from the vial and administered to the host by injection. Example 1 2-β-D-ribofuranosylthiazole-4-
Carboxamide, Compound 1 Ethyl 2-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-thiazole-4
- Carboxamides are described by Srivastova et al., J.D., herein incorporated by reference. Med. Chem. (J.Med.Chem.), 1977, Volume 20, No.
Use as made in No. 2256. Ethyl 2-(2,3,5-tri-O-
Benzyl-β-D-ribofuranosyl)thiazole-4-carboxamide (5.0 g, 8.31 mmol)
A concentrated solution of is stirred with methanolic ammonia (saturated at 0° C., 100 ml) in a pressure bottle at room temperature for 2 days. The solvent was evaporated and the residue was placed on a column of silica gel (100 g) packed in ethyl acetate (2.5 x 35
chromatography through cm). Solvent system (ethyl acetate-1-propanol-water, 4:
When the column is eluted at a ratio of 1:2 (V/V; top layer), methyl benzoate and benzamide move quickly. Most slowly moving UV and sugar-
The sugar-positive fractions are collected and the solvent is evaporated under reduced pressure. The residue thus obtained (syrup-like) was easily crystallized from ethanol-ethyl acetate to yield 1.6 g (74%) of pure product,
Compound 1: mp144â145°C; [α] 25 p â14.3° (C1,
DMF); UVã nax PH 1 237nm (8640); UVã nax PH
11 238nm (8100); 1 HNMR (Mc 2 SOâd 6 ) ÎŽ7.5â
7.8 [S(br), 2, CONH 2 ] 1 HNMR(Mc 2 SOâd 6
âD 2 O) ÎŽ4.99 (d, 1, Jâ5H 2 , H 1 â²), 8.25
(S, 1, H 5 ), analysis (C 9 H 12 N 2 O 5 S) C, H,
Provide N, S, Example 2 2-(2,3,5-tri-O-acetyl-β-
D-ribofuranosyl)thiazole-4-carboxamide, compound 2 Acetic anhydride (2.0ml) was added to anhydrous pyridine (16ml).
of Compound 1 (1.04 g, 4 mmol) in an ice-cold solution and the reaction solution was stirred at room temperature for 17 hours. The solvent is evaporated under reduced pressure, the residue is dissolved in ethyl acetate, the solution is washed with water and dried (MgSO 4 ). The ethyl acetate portion was evaporated under reduced pressure;
The residue thus obtained was crystallized from water to yield 1.4
g (90%) of compound 2 as white needles;
mp103°C; 1 HNMR ( CDCl3 ) 2.1 (3S, 9, tri-O-acetyl), 6.2 and 7.15 [S(br) pair,
2, CONH 2 ], 8.2 (S, 1, H 5 ). analysis,
(C 15 H 18 N 2 O 8 S) C, H, N, S. Example 3 2-(5-O-phosphoryl-β-D-ribofuranosyl)thiazole-4-carboxamide (2-β-D-ribofuranosylthiazole-4
-carboxamide 5'-phosphate), Compound 3 Water (151 mg, 8.4 mmol) was carefully combined with freshly distilled phosphoryl chloride (2.0 g, 13.2 mmol), pyridine (1.21 g, 14.4 mmol) and acetonitrile (2.3 g, 56.7 mmol). mmol) (kept at 0° C. with stirring).
2-β-D-ribofuranosylthiazole-4-carboxamide (compound 1) (800 mg, 3.0 mmol, dried over P 2 O 5 and powdered) was added to this solution and the reaction mixture continued. and 0â for 4 hours
Stir at . Pour the reaction mixture into ice water (approximately 50 ml)
Pour into the solution and adjust the pH to 2.0 with 2N sodium hydroxide. This solution is applied to a column of activated carbon (20 g) and the column is thoroughly washed with water until the eluate is free of salt. The column is eluted with an ethanol-water-concentrated ammonium hydroxide (10:10:1) solution and fractions (25 ml each) are collected. Purification (tlc,
Silica gel, acetonitrile-0.1N ammonium chloride (7:3)) Fractions containing the nucleotide (compound 3) are collected and evaporated to dryness under reduced pressure.
Dissolve the anhydrous residue in water, dowex 50WâX8 (20â50 mesh, H + type, 15
ml) through the column. Wash the column with water and collect the fractions containing the nucleotides. Concentrate the solution to a small volume (5 ml) and use a Dowex 50W-
Pass through a column of X8 (20â50 mesh, Na + form, 15 ml). Wash this column with water. The fraction containing the nucleotides is lyophilized. The residue is triturated with ethanol, collected by filtration and dried (P 2 O 5 ) to yield 560 mg (47%) of compound 3 in crystalline form as monosodium dihydrate. Analysis, Calculated as C 9 H 12 N 2 O 8 PSNaã»2H 2 O: C, 27.13; H, 4.04; N,
7.04; P, 7.78; S, 8.05. Actual values: C, 27.42; H, 3.87; N, 7.07; P, 8.03; S, 8.41. Example 4 2-(5-O-acetyl-β-D-ribofuranosyl)thiazole-4-carboxamide, compound 4 2-(2,3-O-
Isopropylidene-β-D-ribofuranosyl)thiazole-4-carboxamide (1.5 g, 5 mmol) (Fuertes et al., J.Org.Chem., Vol. 41, No. 26 issue,
1976, prepared as 4074) is cooled on an ice-water bath and acetic anhydride (2.5 ml) is added with gentle stirring. Warm the reaction solution to room temperature,
Continue stirring for 15 hours. Evaporate the solvent under reduced pressure,
The residue is dissolved in ethyl acetate and washed with water.
The ethyl acetate portion was evaporated under reduced pressure and the residue was reduced to 80%
Dissolve in % acetic acid (25 ml). The solution is heated on a steam bath for 30 minutes and the solvent is evaporated under reduced pressure. The residue is dissolved in ethyl acetate, washed once with water and dried over MgSO 4 . The ethyl acetate portion was evaporated and the crude product was dissolved in silica gel (100 g,
(packed in chloroform) column and eluted with 20% (v/v) ethyl acetate in chloroform. Fractions containing nucleotides are pooled and evaporated to yield 1.05 g (70%) of compound 4.
( C11H14N2O6S ) . Examples 5 to 12 below are given as demonstrations of Compound 1 and other illustrative compounds of the invention. In these examples, the efficacy of the compounds is demonstrated using standard tests against certain malignancies. The tests used in these demonstrations were conducted under the guidance of the International Cancer Research Institute, Division of Cancer Therapy, and Developmental Therapeutic Project.
This study was conducted using those standard protocols and methods and was supervised by this agency. All tests were conducted in accordance with these agreements, and all studies were evaluated based on the criteria specified by these agreements. The following representative examples illustrate the robust activity exhibited by illustrative compounds of the invention in the International Cancer Research Institute's Screening Tumor Format. In the examples below, the abbreviation IP stands for intraperitoneal;
Also, IV stands for intravenous. Mean and median survival times are calculated by the International Institute for Cancer Research, Division of Cancer Therapy, Developmental Treatment Plans, Screening Data List Professor 14 (Revised 6/78). The contents of the Quantitative Screening Data List, including appropriate revisions, are included herein by reference. In the following demonstration example, excipients used as carriers for drugs were injected into control animals at the same level as the excipients used in drug-treated animals to eliminate the effects of any excipients in this study. (excluding any drugs therein). Example 5 As an indicator of regenerative activity, compound 1 of the invention is screened against L-1210 lymphocytic leukemia in vivo using CD 2 F 1 male mice as the test species. The selected efficacy parameters are based on the median survival time of drug-treated animals versus appropriate control group animals. Both drug-treated and control animals are inoculated IP with 10 5 seed cells of L-1210 lymphoid leukemia into the ascites fluid. One day after tumor inoculation, animals in drug groups are placed under treatment regimen of Compound 1 at dosage levels as listed in Table 1 below. Animals in drug-treated groups are inoculated by IP injection with the test compound appropriately diluted in water at the stated dosage once daily for 5 days. Day 6 is selected as the indicator of drug toxicity. In this example, all drug-treated animals survived for 6 days. Death of drug-treated animals after 6 days is therefore
Death was due to tumor and not drug toxicity. The median date of death in the control group was 8.5 days. As shown in Table 1 below, the median date of death in the drug-treated group was longer than that in the control group at all levels of the treatment drug, and was clearly longer at 50 mg/Kg (drug dose/body weight of test animal) and above. It was. 1st below
The results shown in the table indicate that the drug exhibited positive activity in this fold assay. % of drug-treated animals/control animals greater than or equal to 125% is considered positive drug activity.
ãè¡šã
äŸ ïŒ
ååç©ïŒïŒïŒâïŒïŒïŒïŒïŒïŒâããªââã¢ã»
ãã«âβââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«âïŒ
âã«ã«ããã·ã¢ãããäŸïŒã«ç€ºããåãæ¹æ³ã«ãŠ
ã¹ã¯ãªãŒãã³ã°ããããè©Šéšè
«çãšããŠçšããè
«
çç³»ã¯p388ãªã³ãççœè¡ç
ã§ããã106ã·ãŒã现
èã察ç
§çŸ€ãšè¬å€åŠçœ®çŸ€åæ¹ã®åç©ã«è
«çãã€ã
ãããã«çšãããåã系統ã®ããŠã¹ãçšãããé
ã®ä»£ããã«éã®ããŠã¹ãçšãããè©Šéšçµæã¯å¹³å
çåæéã«åºã¥ããïŒïŒ£çŸåçïŒåŠçœ®åç©ïŒå¯Ÿ
ç
§åç©ïŒãšããŠäŸïŒã«ããåŠãè¡šããã
è¬å€åŠçœ®åç©ã«ã¯ãåŠçœ®ã¯è
«çãæ¥çš®ããŠãã
ïŒæ¥åŸã«å§ããè¬å€ã次ã®ç¬¬ïŒè¡šã«èšèŒããæäž
éã¬ãã«ã«ãŠäžãããè¬å€ã®åŠçœ®ãïŒæ¥éç¶ãã
äŸïŒã«ãããåŠãè¬å€æ¯æ§ãïŒæ¥ç®ã«å€å®ããã
100mgïŒKgã¬ãã«ã§ã¯ãæ¯æ§æã¡åãæ¥ãããé·
ãçåã§ããªãã€ãåç©ã¯ïŒå¹ã§ãã€ãã
察ç
§çŸ€ã§ã®æ»äº¡å¹³åæ¥ã¯10.2æ¥ã§ãããäžæ¹æ
äœã¬ãã«ã®è¬å€åŠçœ®ã§ãåŠçœ®åç©ã¯15æ¥ä»¥äžçå
ãããäŸïŒãšåæ§ã«ãåŠçœ®åç©ã®å¯Ÿç
§åç©ã«æ¯ã¹
ãŠ125ïŒ
å¢ã®é·åœãéœæ§è¬å€åå¿ã®ææšãšã¿ãªãã[Table] Example 6 Compound 2,2-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)thiazole-4
- Carboxamides are screened in the same manner as described in Example 5, but the tumor line used as the test tumor is p388 lymphocytic leukemia. 106 seed cells are used to generate tumors in both control and drug-treated animals. Use the same strain of mice, but use female mice instead of males. The test results are based on the mean survival time and are expressed as T/C percentage (treated animals/control animals) as per Example 5. For drug-treated animals, treatment begins one day after tumor inoculation and drugs are given at the dosage levels listed in Table 2 below. Continue drug treatment for 9 days,
Drug toxicity is determined on day 6 as in Example 5.
At the 100 mg/Kg level, only one animal failed to survive beyond the toxicity cut-off date. The mean day of death in the control group was 10.2 days, while treated animals survived for more than 15 days even at the lowest level of drug treatment. As in Example 5, a 125% increase in longevity in treated animals compared to control animals is considered an indicator of a positive drug response.
ãè¡šã
ååç©ïŒããŸãäŸ6aãïœããã³ïœãšåãã
P388ãªã³ãççœè¡ç
ã«å¯ŸããŠæŽ»æ§ã§ããããšã
瀺ããããŸãååç©ïŒã§ããïŒâïŒïŒïŒïŒïŒïŒâ
ããªââã¢ã»ãã«âβââãªããã©ãã·ã«ïŒ
ãã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããã¯ããã«äŸïŒ
ã«ããåŠãP388ãªã³ãççœè¡ç
ã«å¯ŸããŠæŽ»æ§ã§
ããããšã瀺ãããããããã®äž¡æ¹ã®äŸã«ãã
ãŠãæ¬ååç©ã¯åœéçç 究æè©Šéšã®DN2ïŒæ±ºå®
網ïŒå€å®åºæºã奜çµæã§ééãããäŸïŒããã³ïŒ
ã§ã¯ãCD2F1éããŠã¹ãçšããP388ãªã³ãççœ
è¡ç
è
«çã«ææŠããããè¬å€åŠçœ®åç©ã®çåæé
ã®äžå€®å€ãé©åœãªå¯Ÿç
§åç©ãšæ¯èŒãããã€ãã®å€
å®åºæºã«åºã¥ããŠäž¡æ¹ã®è©Šéšååç©ã掻æ§æè
«ç
å€ãšèãããè©Šéšæéã¯äŸïŒããã³ïŒãšã30æ¥é
ã§ããã
äŸïŒããã³ïŒã§ã¯ã次ã®äŸïŒããã³10ãšåã
ããè©Šéšæéã®çµæ«æ¥ä»¥äžçåãããè¬å€åŠçœ®çŸ€
ã®ãããã®åç©ããããã§è©äŸ¡ããŠïŒçŸ€ã®ïŒã€ã«
å
¥ããã第ïŒçŸ€ã¯æ²»çãããšåŒã°ããåç©ã¯æå
ããŠè
«çãæ²»çããããšãæå³ããã第ïŒçŸ€ã®å
称ã¯åãåããªãïŒnoâtakesïŒã§ãããããã¯
åç©ã®çåãè
«ç移æ®ã®å€±æã«ãããšèãããã
ããšãæå³ãããæ®ãã®çŸ€ã¯è
«ççååç©ãšåŒã°
ããåç©ã¯è©Šéšæã¡åãæ¥ä»¥äžçåãããæ²»çã
ãåã¯åãåããªãã®ãããã«ãåé¡ã§ããªãã
ãšãæå³ããã
äŸïŒããã³ïŒã®äž¡æ¹ãšãã30å¹ã®åç©ã察ç
§çŸ€
ãšããŠçšãããŸããè¬å€åŠçœ®çŸ€ã«ã¯åã
ïŒå¹ã®å
ç©ã次ã®ç¬¬ïŒããã³ïŒè¡šã«ç€ºããåæäžéã¬ãã«
æ¯ã«çšãããäŸïŒããã³ïŒã®äž¡æ¹ã«ãããŠã察ç
§
矀ããã³è¬å€åŠçœ®çŸ€ãšãã«ãè
«çãïŒæ¥ç®ã«è
«ç
ã·ãŒã现èãIPæ¥çš®ããããšã«ãã€ãŠèªçºãã
次ãã§ïŒæ¥ç®ããè¬å€åŠçœ®ãå§ãããäŸ7aãã
ã³ïŒã®äž¡æ¹ãšãããµã©ã€ã³ïŒsalineïŒâããŠã€ãŒ
ã³ïŒtweenïŒïŒ80ãè¬å€è³Šåœ¢å€ãšããŠçšãããäŸ
7bããã³7cã§ã¯ãæ°Žãè¬å€è³Šåœ¢äŸãšããŠçšããã
äŸïŒããã³ïŒã«ããã察ç
§çŸ€ããã³è¬å€åŠçœ®çŸ€
ãšããè©Šéšåç©ã«ã¯ïŒæ¥ç®ã«P388ãªã³ãççœè¡
ç
ã®106ã·ãŒã现èãIPæ¥çš®ãããäŸïŒããã³ïŒ
ãšããè¬å€çŸ€ã®åŠçœ®ã¯ïŒæ¥ç®ã«å§ããè¬å€ãïŒæ¥
ïŒåïŒæ¥éIPæäžãããïŒæ¥ç®ãè¬å€æ¯æ§ã«ã
ãæ»ã®æã¡åãæ¥ãšãããïŒäŸã®ã¿ãäŸ7bã§ã
è¬å€æ¯æ§ã«ããåç©æ»ãã¿ããããåŠçœ®å¹åã¯è¬
å€åŠçœ®åç©ã®çåæéã®äžå€®å€ã察ç
§åç©ã®çå
æéã®äžå€®å€ãšæ¯èŒããããšã«ãã€ãŠæž¬å®ããã
äŸïŒã®åŠãåŠçœ®åç©ïŒå¯Ÿç
§åç©ïŒïŒŽïŒïŒ£ïŒã®çŸå
çå¢å ãšããŠè¡šããããã
äŸ 7a
ãã®äŸã§ã¯è¬å€åŠçœ®åç©ã«ã¯æ¬¡ã®ç¬¬ïŒè¡šã«çšã
ãè¬å€ã¬ãã«ã§IP泚å°ããããïŒå¹ã®åç©ãå
æäžéã¬ãã«æ¯ã«åŠçœ®ããã察ç
§åç©ã§ã¯18æ¥ä»¥
äžçåããåç©ã¯äžå¹ããªããæ»äº¡æ¥ã®äžå€®å€ã¯
12.6æ¥ã§ãã€ããè¬å€åŠçœ®åç©ã®æ»äº¡æ¥ã®äžå€®å€
ã¯æ¬¡ã®ç¬¬3aè¡šã«ç€ºããåŠãã§ããã50mgïŒKgã¬
ãã«ã§ã¯ãè¬å€åŠçœ®åç©ã§ã¯äžå¹ãçåãããã
ãã®åç©ã¯åãåããªããšå€å®ãããã
äŸ 7b
ãã®äŸã¯äŸ7aã®åŠã次ã®ç¬¬3bè¡šã«ç€ºããåŠã
æäžéã¬ãã«ã§è¡ãããã700ããã³800mgïŒKgã¬
ãã«åæ¹ã§ã®çååç©ã¯æ²»çãããšå€å®ãããã
察ç
§åç©ã§ã¯12æ¥ä»¥äžçåããåç©ã¯äžå¹ããª
ãã察ç
§çŸ€ã®å¹³åæ»äº¡æ¥ã¯11æ¥ã§ãã€ãã
äŸ 7c
ãã®äŸã¯æ¬¡ã®ç¬¬3cè¡šã«ç€ºããæäžéã¬ãã«ã«ãŠ
äžèšã®äŸ7aã®åŠãé²ããããã察ç
§åç©ã¯ãã¹
ãŠ14æ¥ãŸã§æ»äº¡ããå¹³åæ»äº¡æ¥ã¯11.9æ¥ã§ãã€
ãã500mgïŒKgã¬ãã«ã§ã¯ãïŒå¹ã®åç©ãæ²»çãš
å€å®ãããã
äŸ ïŒ
ååç©ïŒã§ããïŒâïŒïŒïŒïŒïŒïŒâããªââ
ã¢ã»ãã«âβââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«
âïŒâã«ã«ããã·ã¢ãããã次ã®ç¬¬ïŒè¡šã«ç€ºãã
æäžéã¬ãã«ã«ãŠäŸ7aã®åŠãè©Šéšããã察ç
§ã§
ã¯18æ¥ä»¥äžçåãããã®ã§ã¯ãªããå¹³åæ»äº¡æ¥ã¯
12.6æ¥ã§ãã€ãã50mgïŒKgã¬ãã«ã§ã¯ãçåãã
äžå¹ã®åç©ã¯åãåããªããšå€å®ãããã
ååç©ïŒããã³ïŒãšãäŸïŒããã³ïŒã«ãããŠç€º
ããåéç 究ã«ãããŠæŽ»æ§æè
«çå€ã§ããããšã
èªããããã[Table] Compound 1 is also similar to Example 6a, b and c.
Compound 2, 2-(2,3,5-
tri-O-acetyl-β-D-ribofuranosyl)
Thiazole-4-carboxamide is further prepared in Example 7
It was shown to be active against P388 lymphocytic leukemia. In both of these examples, the compounds successfully passed the DN2 (Decision Net) criteria of the International Institute for Cancer Research testing. Examples 7 and 8
Here, CD2F1 female mice were challenged with P388 lymphocytic leukemia tumors. Median survival times of drug-treated animals are compared to appropriate control animals, and both test compounds are considered active anti-tumor agents based on this criterion. The test period was 30 days in both Examples 7 and 8. In Examples 7 and 8, as in Examples 9 and 10 below, any animal in the drug-treated group that survives beyond the end of the study period is then evaluated and placed in one of the three groups. The first group was called cured, meaning the animals were successfully treated for the tumor. The second group is named no-takes, meaning that the survival of the animals is considered to be due to failure of tumor engraftment. The remaining group is referred to as tumor survivors, meaning that the animals survived beyond the study termination date but cannot be classified as either cured or non-receiving. Both Examples 7 and 8 used 30 animals as a control group and drug treatment groups with 6 animals each for each dose level shown in Tables 3 and 4 below. In both Examples 7 and 8, tumors in both control and drug-treated groups were induced by IP inoculation with tumor seed cells on day 0;
Drug treatment is then started on the first day. Both Examples 7a and 8 use saline-tween/80 as the drug excipient. example
In 7b and 7c, water is used as the drug excipient. For both the control and drug-treated groups in Examples 7 and 8, test animals are inoculated IP with 10 6 seed cells of P388 lymphocytic leukemia on day 0. Examples 7 and 8
In both drug groups, treatment begins on day 1, with drug administered IP once daily for 9 days. Day 6 is the censoring date for death due to drug toxicity. In only one case, example 7b,
Animal deaths due to drug toxicity were observed. Treatment efficacy is determined by comparing the median survival time of drug-treated animals to the median survival time of control animals;
Expressed as a percentage increase in treated animals/control animals (T/C) as in Example 5. Example 7a In this example, drug-treated animals are given IP injections at the drug levels used in Table 3 below. Six animals are treated at each dose level. None of the control animals survived for more than 18 days, and the median date of death was
It was 12.6 days. Median dates of death for drug-treated animals are shown in Table 3a below. At the 50 mg/Kg level, one drug-treated animal survived;
This animal was marked as not received. Example 7b This example is conducted as in Example 7a at the dosage levels as shown in Table 3b below. Surviving animals at both the 700 and 800 mg/Kg levels were considered cured.
None of the control animals survived for more than 12 days, and the average date of death for the control group was 11 days. Example 7c This example proceeds as in Example 7a above at the dosage levels shown in Table 3c below. All control animals died by day 14, with an average date of death of 11.9 days. At the 500 mg/Kg level, one animal was deemed cured. Example 8 Compound 2, 2-(2,3,5-tri-O-
Acetyl-β-D-ribofuranosyl)thiazole-4-carboxamide is tested as in Example 7a at the dosage levels shown in Table 4 below. None of the controls survived more than 18 days, and the average date of death was
It was 12.6 days. At the 50 mg/Kg level, one animal that survived was declared a non-receiver. Both compounds 1 and 2 are found to be active antitumor agents in the fold studies presented in Examples 7 and 8.
ãè¡šããtableã
ãè¡šããtableã
ãè¡šããtableã
ãè¡šã
ååç©ïŒã¯äŸïŒã®åŠãâ1210ãªã³ãæ§çœè¡ç
ã«å¯ŸããŠæŽ»æ§ã§ããããšã瀺ããããã€åœéçç
究æè©Šéšã®DN2å€å®åºæºãæåè£ã«ééããã
äŸ9aããã³9bã§ã¯ãCD2R1éããŠã¹ãçšããŠïŒ¬
â1210ãªã³ãæ§çœè¡çã«ææŠããŠã¿ããè©Šéšåç©
ã®å¹³åçåæéãé©åœãªå¯Ÿç
§åç©ãšæ¯èŒãããã€
ãã®å€å®åºæºã«åºã¥ããŠãååç©ïŒã掻æ§ãªæè
«
çå€ãšã¿ãªãããè©Šéšæéã¯30æ¥ã§ãã€ããè©Šéš
çµæãäŸïŒã®åŠãïŒïŒ£ãšããŠè¡šããã
äŸ9aã§ã¯ã24å¹ã®å¯Ÿç
§åç©ãçšãã次ã®ç¬¬5a
è¡šã«ç€ºããåŠãåè¬å€æäžéã«ã¯ïŒå¹ã®åç©ãçš
ãããäŸ9bã§ã¯ã40å¹ã®å¯Ÿç
§åç©ãçšãããã
ãŠæ¬¡ã®ç¬¬5bè¡šã«ç€ºããåŠãè¬å€æäžéã¬ãã«ã«
ã¯å10å¹ã®è©Šéšåç©ãçšããã察ç
§çŸ€ããã³è¬å€
è©ŠéšçŸ€ãšãã«ãè
«çãïŒæ¥ç®ã«è
«çã·ãŒã现èã®
IPæ¥çš®ã«ããèªçºãã次ãã§ïŒæ¥ç®ããè¬å€åŠ
眮ãå§ãããäŸ9aã§ã¯æ°Žãè¬å€è³Šåœ¢å€ãšããŠçš
ããäŸ9bã§ã¯ãµã©ã€ã³ãè¬å€è³Šåœ¢å€ãšããŠçšã
ãã
äŸ9aããã³9bã§ã¯å¯Ÿç
§çŸ€ããã³è¬å€åŠçœ®çŸ€ãš
ãã«ãè©Šéšåç©ã«ã¯ïŒæ¥ç®ã«ïŒ¬â1210ãªã³ãæ§çœ
è¡çã®106ã·ãŒã现èãIPæ¥çš®ãããäŸ9aã§ã¯ã
è¬å€åŠçœ®ãïŒæ¥ç®ã«å§ããååç©ïŒãïŒæ¥ïŒåïŒ
æ¥éæäžãããïŒæ¥ãè¬å€æ¯æ§ã«ããæ»ã®æã¡å
ãæ¥ãšãããäŸ9bã§ã¯ãããïŒäŸã®ã¿ã«è¬å€æ¯
æ§ã«ããæ»äº¡ãã¿ããããåŠçœ®å¹åãè¬å€åŠçœ®å
ç©ã®å¹³åçåæéãšå¯Ÿç
§åç©ã®å¹³åçåæéãšã®
æ¯èŒã«ãã€ãŠæž¬å®ãããã€ãããäŸïŒã®åŠãåŠçœ®
åç©ïŒå¯Ÿç
§åç©ïŒïŒŽïŒïŒ£ïŒã®çŸåçå¢å ãšããŠè¡š
ããã
äŸ 9a
ãã®äŸã§ã¯ãè¬å€åŠçœ®åç©ã«ã¯æ¬¡ã®ç¬¬5aè¡šã«
瀺ããåŠãæäžéã¬ãã«ãIP泚å°ãããïŒå¹ã®
åç©ãåæäžéã¬ãã«æ¯ã«çšããã察ç
§åç©ã§ã¯
10æ¥ä»¥äžçåããåç©ã¯äžå¹ããªããå¹³åæ»äº¡æ¥
ã¯9.7æ¥ã§ãã€ããè¬å€åŠçœ®åç©ã®å¹³åæ»äº¡æ¥ã¯
次ã®ç¬¬5aè¡šã«ç€ºããåŠãã§ããã
äŸ 9b
ãã®äŸã§ã¯ãè¬å€åŠçœ®åç©ã«æ¬¡ã®ç¬¬5bè¡šã«ç€º
ããæäžã¬ãã«ãIP泚å°ããã10å¹ã®åç©ã«å
æäžã¬ãã«ãåŠçœ®ããã察ç
§åç©ã§ã¯10æ¥ä»¥äžç
åããåç©ã¯äžå¹ããªããå¹³åæ»äº¡æ¥ã¯9.0æ¥ã§
ãã€ããåŠçœ®åç©ã®å¹³åæ»äº¡æ¥ã¯æ¬¡ã®5bè¡šã«ç€º
ããéãã§ãããTable: Compound 1 was shown to be active against L-1210 lymphoid leukocytes as in Example 9 and successfully passed the DN2 criteria of the International Cancer Research Institute test.
In Examples 9a and 9b, CD2R1 male mice were used to
I tried -1210 lymphoid leukocytes. The mean survival time of the test animals was compared to appropriate control animals, and based on this criterion, Compound 1 was considered an active anti-tumor agent. The test period was 30 days. The test results are expressed as T/C as in Example 5. Example 9a uses 24 control animals and the following 5a
Six animals were used for each drug dose as indicated in the table. In Example 9b, 40 control animals were used and 10 test animals were used for each drug dose level as shown in Table 5b below. In both the control group and the drug test group, tumors were injected with tumor seed cells on day 0.
Challenge by IP inoculation, then start drug treatment on day 1. Example 9a uses water as the drug excipient and Example 9b uses Saline as the drug excipient. In Examples 9a and 9b, test animals are inoculated IP with 10 6 seed cells of L-1210 lymphoid leukocytes on day 0 for both control and drug-treated groups. In example 9a,
Drug treatment started on day 1, with Compound 1 once daily 9
Administer for days. Day 5 is the censoring date for death due to drug toxicity. In case 9b, only one patient died due to drug toxicity. Treatment efficacy is determined by comparison of the mean survival time of drug-treated animals to the mean survival time of control animals and is expressed as a percentage increase in treated animals/control animals (T/C) as in Example 5. Example 9a In this example, drug-treated animals are injected IP at dose levels as shown in Table 5a below. Six animals are used for each dose level. In control animals
None of the animals survived for more than 10 days, and the average date of death was 9.7 days. The average date of death for drug-treated animals is as shown in Table 5a below. Example 9b In this example, drug-treated animals are injected IP at the dose levels shown in Table 5b below. Ten animals are treated at each dose level. None of the control animals survived for more than 10 days, and the average date of death was 9.0 days. The average date of death for treated animals is shown in Table 5b below.
ãè¡šããtableã
ãè¡šã
ååç©ïŒã¯ã«ã€ã¹ïŒLewisïŒèçã«å¯ŸããŠäŸ10
ã®åŠã掻æ§ã§ããããšã瀺ããããã€åœéçç 究
æè©Šéšã®DN2å€å®åºæºãæåè£ã«ééãããäŸ
10ã§ã¯ãB6D2F1éããŠã¹ãçšãããã€ã«ã€ã¹è
çã«ææŠãããè©Šéšåç©ã®çåæéã®äžå€®å€ãé©
åœãªå¯Ÿç
§åç©ãšæ¯èŒãããã€ãã®å€å®åºæºã«åºã¥
ããŠååç©ïŒãæå¹ãªæè
«çå€ãšèããã
äŸ10ã§ã¯ã40å¹ã®åç©ã察ç
§çŸ€ã«çšãã次ã®ç¬¬
ïŒè¡šã«ç€ºããæäžã¬ãã«ã«ã¯å10å¹ã®è©Šéšåç©ã
çšããã察ç
§çŸ€ããã³è¬å€åŠçœ®çŸ€ãšãã«ãè
«çã
ïŒæ¥ç®ã«IV泚å°ã«ãã€ãŠèªçºãããç¶ããŠïŒæ¥
ç®ããè¬å€åŠçœ®ãå§ãããäŸ10ã§ã¯æ°Žãè¬å€è³Šåœ¢
å€ãšããŠçšããã
äŸ10ã§ã¯å¯Ÿç
§çŸ€ããã³è¬å€åŠçœ®çŸ€ãšãã«ãåç©
ã«ã¯ïŒæ¥ç®ã«ã«ã€ã¹èçã®106ã·ãŒã现èã®ãã¢
ãžãšããŒããæ¥çš®ãããäŸ10ã§ã¯ãè¬å€åŠçœ®ãïŒ
æ¥ç®ã«å§ããååç©ïŒãïŒæ¥ïŒåïŒæ¥éæäžã
ããïŒæ¥ç®ãè¬å€æ¯æ§ã«ããæ»äº¡ã®æã¡åãæ¥ãš
ããããã®äŸã§ã¯è¬å€æ¯æ§ã«ããæ»äº¡ã¯ïŒä»¶ããª
ãã€ããåŠçœ®å¹åã¯è¬å€åŠçœ®åç©ã®çåæéã®äž
倮å€ã察ç
§åç©ã®çåæéã®äžå€®å€ãšæ¯èŒããã
ãšã«ãã€ãŠæž¬å®ããããããäŸïŒã®åŠãåŠçœ®å
ç©ïŒå¯Ÿç
§åç©ïŒïŒŽïŒïŒ£ïŒã®çŸåçå¢å ãšããŠè¡šã
ãã
è©Šéšæéã¯60æ¥éã§ããã60æ¥æéã®çµããã«
è©ŠéšçŸ€ã®äžã§çåããŠããåç©ãäžèšäŸïŒã®åŠã
æ²»çãããåãåããªããåã¯è
«ççååç©ã®ã
ããã§ããããè©äŸ¡ããã
äŸ 10
ãã®äŸã§ã¯ãè¬å€åŠçœ®åç©ã«æ¬¡ã®ç¬¬ïŒè¡šã«ç€ºã
ãæäžã¬ãã«ãIP泚å°ãããåæäžã¬ãã«æ¯ã«
10å¹ã®åç©ãçšããã察ç
§åç©ã§ã¯23æ¥ä»¥äžçå
ããåç©ã¯äžå¹ããªããæ»äº¡æ¥ã®äžå€®å€ã¯18.4æ¥
ã§ãã€ãã400ã200ããã³25mgïŒKgã®è©Šéšã¬ãã«
ã§ã¯ããã¹ãŠã®åç©ã60æ¥ã®è©Šéšæéäžçåã
ãããã®äºå®ã«ããã次ã®ç¬¬ïŒè¡šã«ç€ºããïŒïŒ£
æ¯çã¯ãåŠçœ®åç©ã®çåæ¥60ãšå¯Ÿç
§åç©ã®äžå€®æ»
亡æ¥18.4æ¥ããèšç®ãããšäžå®ã®æ°å€ããšãã
äŸ10ã§ã¯200ããã³400mgïŒKgã¬ãã«ãšãã10å¹
ã®çåè©Šéšåç©ã¯ãã¹ãŠæ²»çãããšå€å®ãããã
100mgïŒKgã¬ãã«ã§ã¯ãïŒå¹ãæ²»çããïŒå¹ã¯è
«
ççååç©ã§ïŒå¹ã¯46æ¥ç®ã«æ»äº¡ããã50mgïŒKg
ã¬ãã«ã§ã¯ãïŒå¹ãæ²»çããïŒå¹ã¯47æ¥ç®ã«æ»äº¡
ããã
ååç©ïŒã¯äŸ10ã«ç€ºããåéç 究ã§æŽ»æ§æè
«ç
å€ã§ããããšãèªããããã[Table] Compound 1 against Lewis liver cancer in case 10
It was shown to be as active as in the US and successfully passed the DN2 criteria of the International Cancer Research Institute test. example
In 10 , B6D2F1 male mice were used and challenged with Lewis liver carcinoma. The median survival time of test animals is compared to appropriate control animals, and based on this criterion Compound 1 is considered an effective anti-tumor agent. In Example 10, 40 animals are used for the control group and 10 test animals are used for each of the dose levels shown in Table 6 below. For both control and drug-treated groups, tumors are induced by IV injection on day 0, followed by drug treatment beginning on day 1. Example 10 uses water as the drug excipient. In Example 10, animals are inoculated with a homogenate of 10 6 seed cells of Lewis hepatoma on day 0 for both control and drug-treated groups. In Example 10, drug treatment was
Starting on day 1, Compound 1 is administered once daily for 9 days. Day 5 is the censoring date for deaths due to drug toxicity. In this case, there were no deaths due to drug toxicity. Treatment efficacy is determined by comparing the median survival time of drug-treated animals to the median survival time of control animals, which is expressed as a percentage increase in treated animals/control animals (T/C) as in Example 5. Expressed as The test period is 60 days, and at the end of the 60 day period, surviving animals in the test group are evaluated as cured, nonrecipient, or tumor survivors as in Example 5 above. Example 10 In this example, drug-treated animals are injected IP with the dose levels shown in Table 6 below. For each dose level
Use 10 animals. None of the control animals survived for more than 23 days, and the median date of death was 18.4 days. At test levels of 400, 200 and 25 mg/Kg, all animals survived the 60 day test period. Due to this fact, the T/C shown in Table 6 below
The ratio is constant when calculated from the median survival date of 60 days for treated animals and the median death date of 18.4 days for control animals. In Example 10, all 10 surviving test animals at both the 200 and 400 mg/Kg levels were determined to be cured.
At the 100 mg/Kg level, 8 animals were cured, 1 tumor survivor and 1 animal died on day 46. 50mg/Kg
At the level, 9 were cured and 1 died on day 47. Compound 1 was shown in Example 10 and was found to be an active anti-tumor agent in a fold study.
ãè¡šã
äžèšã®äŸ10ã«ç€ºããåŠããååç©ïŒã¯ã«ã€ã¹è
çã«å¯ŸãèæãªæŽ»æ§ã瀺ããã«ã€ã¹èçã¯è»¢ç§»è
«
çç³»ã®é¡èãªäŸã§ãããäŸ10ã®è©Šéšããã³å¯Ÿç
§å
ç©ã«è
«çã®ãã¢ãžãšããŒããIVæ¥çš®ããããã®
è
«çã®åçãªåŸ®äŸ¯ã¯èèã«è¡šããããåèšã®åŠ
ãã転移ããèœåã¯æªæ§è
«çãè¯æ§è
«çãšèå¥ã
ãå¯äžã®ç¹æ§ã§ãããäŸ10ã§ã¯ãè¬å€åŠçœ®åç©ã®
çåæéã®äžå€®å€ãé©ãã»ã©å»¶é·ããã®ã¿ãªã
ããè©Šéšæéã®çµããã«ã¯ãïŒã€ã®æäžã¬ãã«ã
é€ããå°ããšã80ïŒ
æ²»çãèªãããããŸãããã
ã¬ãã«ã®ïŒã€ã§ã¯100ïŒ
æ²»çãååšããã
äŸ 11
ååç©ïŒã§ããïŒâïŒïŒââãã¹ããªã«âβ
ââãªããã©ãã·ã«ïŒãã¢ãŸãŒã«âïŒâã«ã«ã
ãã·ã¢ããã¯äŸ11aããã³11bã®åŠãâ1210ãª
ã³ãæ§çœè¡çã«å¯ŸããŠæŽ»æ§ã§ããããšã瀺ãã
ãããããã®äŸã¯ç¹ã«èšåããªãéãäžèšäŸïŒãš
æ¬è³ªçã«ã¯åæ§ã«è¡ããããååç©è©Šéšæäžéã¬
ãã«ã¯ãäŸ11aããã³11båã
ã«ãããŠæ¬¡ã®ç¬¬7a
ããã³7bè¡šã«èšèŒããåŠãã§ããããããã®äŸ
ã§ã¯ã36å¹ã®å¯Ÿç
§åç©ãçšãã第7aããã³7bè¡š
ã«ç€ºããåŠãè¬å€æäžã¬ãã«ã«ã¯åã
ïŒå¹ã®è©Šéš
åç©ãçšããããµã©ã€ã³ãè¬å€è³Šåœ¢å€ãšããŠçšã
ããäŸ11aåã¯11bã®ãããã«ãããŠãè©Šéšåç©
ã«ã¯è¬å€æ¯æ§ã¯ã¿ãããªãã€ãã察ç
§åç©ã®çå
ã¯äŸ11aã§ã¯10æ¥ä»¥äžã¯äžå¹ããªãããã®å¹³åæ»
亡æ¥ã¯8.3æ¥ã§ããããŸãäŸ11bã§ã¯11æ¥ä»¥äžã¯äž
å¹ããªãããã®å¹³åæ»äº¡æ¥ã¯10.1æ¥ã§ãã€ãã
察ç
§çŸ€ããã³è¬å€è©ŠéšçŸ€ãšãã«ãè
«çã·ãŒã现
èãïŒæ¥ç®ã«IPæ¥çš®ããããšã«ãã€è
«çãèªçº
ãã次ã«ååç©ïŒãïŒæ¥ïŒåïŒæ¥éæäžããè¬å€
æäžãïŒæ¥ç®ããå§ãããè©ŠéšçµæãäŸïŒãšåæ§
ã«ïŒŽïŒïŒ£ãšããŠè¡šããã[Table] As shown in Example 10 above, Compound 1 shows significant activity against Lewis liver cancer. Lewis liver cancer is a prominent example of a metastatic tumor system. The test and control animals of Example 10 are inoculated IV with tumor homogenate. The dramatic features of this tumor appear in the liver. As mentioned above, the ability to metastasize is the only characteristic that distinguishes malignant tumors from benign tumors. In Example 10, not only was the median survival time of the drug-treated animals surprisingly prolonged, but at the end of the study period there was at least 80% cure at all but one dose level, and at two of those levels. There was 100% cure. Example 11 Compound 3, 2-(5-O-phosphoryl-β
-D-ribofuranosyl)thiazole-4-carboxamide was shown to be active against L-1210 lymphoid leukocytes as in Examples 11a and 11b. These examples are conducted essentially the same as Example 9 above unless otherwise noted. Compound test dose levels are as follows in Section 7a in each of Examples 11a and 11b.
and as described in Table 7b. In these examples, 36 control animals were used and 6 test animals were used for each drug dose level as shown in Tables 7a and 7b. Saline was used as a drug excipient. No drug toxicity was observed in the test animals in either Example 11a or 11b. None of the control animals survived longer than 10 days in Example 11a, with an average date of death of 8.3 days, and in Example 11b, none survived longer than 11 days, with an average date of death of 10.1 days. . In both the control group and the drug test group, tumors are induced by IP inoculation of tumor seed cells on day 0, and then drug administration begins on day 1, with Compound 3 administered once daily for 5 days. The test results are expressed as T/C as in Example 5.
ãè¡šããtableã
ãè¡šã
äŸ 12
äŸ12ã§ã¯ãååç©ïŒããã«ã€ã¹èã·ãŒã现èã
é èå
æ¥çš®ããããšã«ãã眹æ£ããè³è
«çãã€ã
ã€AKD2F1ããŠã¹çŸ€ã«IPæäžããã次ã®ç¬¬ïŒè¡šã®
çµæãããããããã«çœ¹æ£åç©ãžã®ååç©ïŒã®
IPæ¥çš®ã¯è³è
«çã®æžå°ããããããããã¯çœ¹æ£
åç©ãžååç©ïŒãIPæ¥çš®ããããšã«ããè¡æ¶²è³
é¢éïŒbarrierïŒã®äº€åããããŸããã€ãããšã
瀺ããŠããã
ãã®è©Šéšã§ã¯ã32å¹ã®å¯Ÿç
§åç©ãçšãããã察
ç
§åç©ã§ã¯11æ¥ä»¥äžçåããã®ã¯äžå¹ããªãã察
ç
§çŸ€ã®å¹³åæ»äº¡æ¥ã¯9.6æ¥ã§ãã€ãã第ïŒè¡šã«ç€º
ããåŠã300mgïŒKgã¬ãã«ãé€ããŠã¯åè¬å€æäž
ã¬ãã«æ¯ã«ïŒå¹ã®è©Šéšåç©ãçšãããè¬å€è³Šåœ¢å€
ãšããŠã¯æ°Žãé€ããã察ç
§çŸ€ããã³è©ŠéšçŸ€ãšã
ã«ãè
«çãïŒæ¥ç®ã«èªçºããååç©ïŒãïŒæ¥ïŒå
ïŒæ¥éæäžããè¬å€åŠçœ®ãïŒæ¥ç®ããéå§ããã
è©ŠéšçµæãäŸïŒã®åŠãïŒïŒ£ãšããŠè¡šãããEXAMPLE 12 In Example 12, Compound 1 is administered IP to a group of AKD 2 F 1 mice that are infected and develop brain tumors by intracranial inoculation with Lewis liver seed cells. As can be seen from the results in Table 8 below, the effects of Compound 1 on affected animals
IP inoculation resulted in a reduction in brain tumors, indicating that IP inoculation of Compound 1 to affected animals successfully crossed the blood-brain barrier. Thirty-two control animals were used in this study, and none of the control animals survived for more than 11 days, and the average date of death for the control group was 9.6 days. Eight test animals were used for each drug dose level except for the 300 mg/Kg level as shown in Table 8. Water was excluded as a drug excipient. In both the control and test groups, tumors were induced on day 0, and drug treatment with Compound 1 administered once daily for 9 days was started on day 1.
The test results are expressed as T/C as in Example 5.
ãè¡šã
å®ã«å€ãã®ç
åè«ç±æ¥ã®ãããã³å®¿äž»ã®æ©èœé
害ç±æ¥åæ¹ã®è³çŸæ£ç¶æ
ã§ã¯ãæ²»çã¯è¬å€ãè¡æ¶²
è³é¢éãè¶ããŠç§»åããªãããã«æå¶ããããçŸ
æ£ç¶æ
ã«å¯Ÿããé©åœãªæ²»çãç¥ãããŠããããçš®
ã®å Žåã«ã¯ããããã®çŸæ£ãæ²»çäžããããé è
å
ã«ããæã«ã¯ãæå¹æ¿åºŠã®é©åœãªååŠçæ³å€ã
è¡æ¶²è³é¢éãè¶ããŠç§»åããªãããã«å䜵çãèµ·
ããåŸãã第ïŒè¡šãããããåŠããååç©ïŒãè¡
液è³é¢éãããŸãééãããšãã城åã¯ãè³è
«ç
ã®æ²»çã«ãšã€ãŠéåžžã«å°æ¥ææã§ããã
次ã®ä»£è¡šäŸ13ãªãã17ã¯ãäŸèšŒæ
äœãçšããäŸ
蚌è¬å€çµæç©äžã«æ¬çºæã®æŽ»æ§ååç©ãå«ãåŠæ¹
ã瀺ãããã®ã§ããããããã®äŸäžãäŸ13ã¯æ¬çº
æã®ååç©ã®éèå
åã¯ä»ã®åœ¢æ
ã®æ³šå°ã«é©åãª
泚å°å€ãšããŠã®å®¿äž»åç©ãžã®äœ¿çšãäŸèšŒãããã®
ã§ãããäŸ14ã¯çµå£ã·ããã補å€ã«ã€ããŠèšèŒã
ããã®ã§ãããäŸ15ã¯çµå£ã«ãã»ã«è£œå€ã«ã€ã
ãŠããããŠäŸ16ã¯çµå£é å€ã«ã€ããŠèšèŒãããã®
ã§ãããäŸ17ã¯é©åœãªåå€ãšããŠã®æ¬çºæã®åå
ç©ã®äœ¿çšã«ã€ããŠèšèŒãããã®ã§ãããäŸ13ãªã
ã17ã§ã¯æåãæãã次ã«çµæç©ã®è£œé æ¹æ³ãèš
èŒããã
äŸ 13
泚å°å€
äŸ13a ååç©ïŒ
ååç©ïŒ 250mgâ1000mg
泚å°çšæ°ŽUSPé©é
ååç©ïŒãæ°Žäžã«æº¶ããããã€0.22ÎŒãã€ã«ã¿
ãŒãéããã液ãã¢ã³ãã«åã¯ãã€ã¢ã«ã«æ·»å
ããå¯å°ãããã€æ®ºèããã
äŸ 13b
ååç©ïŒ
ãããªãŠã å¡©ãšããŠã®ååç©ïŒ 25mgâ1000mg
泚å°çšæ°ŽUSPé©é
äžèšã®äŸ3aãšåæ§ã«è£œé ããã
äŸ 14
ã·ãããå€
äŸ14a ååç©ïŒ
250mg掻æ§æåïŒïŒmlã·ããã
ååç©ïŒ 50ïœ
粟補氎USP 200ml
ããšãªãŒã·ãããé©éå㯠1000ml
ååç©ïŒãæ°Žäžã«æº¶ããããã®æº¶æ¶²ãžã·ããã
ã軜ãæ¹æããªããæ·»å ããã
äŸ 14b
ååç©ïŒ
250mg掻æ§æåïŒïŒmlã·ããã
ãããªãŠã å¡©ãšããŠã®ååç©ïŒ 50.0ïœ
粟補氎USPé©éå㯠200ml
ããšãªãŒã·ãããé©éå㯠1000ml
äŸ 15
ã«ãã»ã«å€
äŸ15a ååç©ïŒ
100mgã250mgåã¯500mg
ååç©ïŒ 500ïœ
ä¹³ç³USPãç¡æ°Žé©éå㯠200ïœ
ã¹ããããã¯ã¹ç²æ«HM ïŒïœ
ååç©ïŒããã³ä¹³ç³ãå¢åŒ·æ£ïŒintensifier
barïŒãåãã察ã®å®¹åšãããªãé
åæ©äžã«ãŠå
䜵ãããæ¿ããé
åãïŒåéè¡ã€ãŠããå¢åŒ·æ£ã
çšããŠïŒåéé
åãã次ã«åã³æ¿ããé
åãïŒå
éè¡ãã次ã«é
åç©ã®äžéšãã¹ããããã¯ã¹ç²æ«
ãšæ··åããïŒ30ãã€ã«ãéãããããæ®ãã®å
ã®
é
åç©äžãžæ»ããæ··åæåã次ã«ïŒåéé
åãã
å¢åŒ·æ£ã§30ç§éé
åãããããŠããã«ïŒåéæ¿ã
ãæ¹æãããé©åœãªå€§ããã®ã«ãã»ã«ã«100mgã
250mgããã³500mgå«æã«ãã»ã«å€ãšããŠãåã
é
åç©ã141mgã352.5mgåã¯705mgå
å¡«ããã
äŸ15b ååç©ïŒ
100mgã250mgåã¯500mg
ååç©ïŒ 500ïœ
ä¹³ç³USPãç¡æ°Žé©éå㯠200ïœ
ã¹ãããã¯ã¹ç²æ«HM ïŒïœ
äŸ15aã®åŠãæ··åãããã€å
å¡«ããã
äŸ15c ååç©ïŒ
100mgã250mgåã¯500mg
ååç©ïŒ 500ïœ
ä¹³ç³USPãç¡æ°Žé©éå㯠200ïœ
ã¹ãããã¯ã¹ç²æ«HM ïŒïœ
äŸ15aã®åŠãæ··åãããã€å
å¡«ããã
äŸ 16
é å€
äŸ16a ååç©ïŒ
100mgã200mgåã¯500mg
ååç©ïŒ 500ïœ
ã³ãŒã³ã¹ã¿ãŒãNF 200.0ïœ
ã»ã«ããŒã¹ã埮æ¶è³ª 46.0ïœ
ã¹ããããã¯ã¹ç²æ«HM 4.0ïœ
粟補氎é©éå㯠300.0ml
ã³ãŒã³ã¹ã¿ãŒããã»ã«ããŒã¹ããã³ååç©ïŒã
ãã©ãã¿ãªãŒïŒplantaryïŒæ··åæ©äžã§äžç·ã«å䜵
ãããã€ïŒåéæ··åããããã®å䜵ç©ãžæ°Žãæ·»å
ããŠïŒåéæ··åãããåŸãããæ··åç©ãçã®äžã«
ã²ãããç±é¢šãªãŒãã³å
ã§50âã«ãŠæ¹¿åºŠãïŒãªã
ãïŒïŒ
ã«ãªããŸã§ä¹Ÿç¥ãããã次ã«ä¹Ÿç¥æ··åç©ã
ãã€ãããã«ïŒFitzmillïŒã§ç²æ«ç¶ã«ããäžäœã®
éãã«ïŒRH2Bãã€ã«ãéããã¹ããããã¯ã¹ç²
æ«ãæ··åç©ã®äžéšãžæ·»å ãããã€ïŒ30ãã«ã€ãé
ãããããå
ã®ç²æ«ç¶æ··åç©ãžæ»ããå
šäœãïŒå
éåç圢éšãå転ãããããšã«ãã€ãŠé
åããã
åã
150mgã375mgããã³750mgã®ç·æ··åç©ã®å§çž®
é å€ã100mgã250mgåã¯500mgå«æé å€ãšããŠé©
åœãªå€§ããã®ãã³ãã§æ圢ããã
äŸ 17
åå€
äŸ17a ååç©ïŒ
250mgã500mgåã¯1000mgïŒïŒïœ
ååç©ïŒ 250mg 500mg 1000mg
ããªãšãã¬ã³ã°ãªã³ãŒã«1540
1925mg 1750mg 1400mg
ããªãšãã¬ã³ã°ãªã³ãŒã«8000
825mg 750mg 600mg
ããªãšãã¬ã³ã°ãªã³ãŒã«1540ãšããªãšãã¬ã³ã°
ãªã³ãŒã«8000ãäžç·ã«60âã§è解ããååç©ïŒã
ãã®èæç©äžãžæº¶ããããã®å
šäœã25âã§é³åã«
å
¥ããŠé©åœãªåå€ãã€ããã
äŸ17b ååç©ïŒ
250ã500ã1000mgïŒïŒïœ
ååç©ïŒ 250mg 500mg 1000mg
ããªãšãã¬ã³ã°ãªã³ãŒã«1540
1925mg 1750mg 1400mg
ããªãšãã¬ã³ã°ãªã³ãŒã«8000
825mg 750mg 600mg
äžèšã®äŸ17aãšåæ§ã«ããŠè£œé ãããTable: In many brain disease states, both pathogenic and host dysfunction, treatment is inhibited because the drug does not cross the blood-brain barrier. In certain cases where appropriate treatments for disease states are known, effective concentrations of appropriate chemotherapeutic agents do not cross the blood-brain barrier when they are intracranial during the treatment of these diseases. can cause complications. As can be seen from Table 8, the indication that Compound 1 successfully crosses the blood-brain barrier is very promising for the treatment of brain tumors. The following Representative Examples 13-17 illustrate formulations containing active compounds of the invention in illustrative pharmaceutical compositions using illustrative carriers. Among these examples, Example 13 illustrates the use of a compound of the invention in a host animal as an injectable solution suitable for intravenous or other forms of injection. Example 14 describes an oral syrup formulation, Example 15 describes an oral capsule formulation, and Example 16 describes an oral tablet formulation. Example 17 describes the use of a compound of the invention as a suitable suppository. Examples 13-17 list the ingredients and then describe the method of making the compositions. Example 13 Injection Example 13a Compound 1 Compound 1 250mg-1000mg Water for Injection USP appropriate amount Dissolve Compound 1 in water and pass through a 0.22ÎŒ filter. Add the filtrate to an ampoule or vial, seal, and sterilize. Example 13b Compound 3 Compound 3 as the sodium salt 25 mg - 1000 mg Water for Injection USP dosage Prepared as in Example 3a above. Example 14 Syrup Example 14a Compound 1 250 mg active ingredient/5 ml syrup Compound 1 50 g Purified water USP 200 ml Thierry syrup as appropriate or 1000 ml Dissolve Compound 1 in water and add the syrup to this solution with gentle stirring. Example 14b Compound 3 250mg active ingredient/5ml Compound 3 as syrup sodium salt 50.0g Purified water USP as required or 200ml Thiery syrup as required or 1000ml Example 15 Capsule Example 15a Compound 1 100mg, 250mg or 500mg Compound 1 500g Lactose USP, anhydrous Appropriate amount or 200g Stelotex powder HM 5g Compound 1 and lactose intensifier
The mixture is combined in a blender consisting of a pair of containers (bar). Blend vigorously for 2 minutes, then blend for 1 minute using the intensifier wand, then vigorously blend again for 1 minute. A portion of the formulation is then mixed with the Sterotex powder, passed through a #30 film, and passed back into the rest of the original formulation. The mixed ingredients are then blended for 1 minute;
Blend for 30 seconds with an intensifier rod and mix vigorously for an additional minute. 100mg in an appropriately sized capsule,
Capsules containing 250 mg and 500 mg are filled with 141 mg, 352.5 mg or 705 mg of the formulation, respectively. Example 15b Compound 2 100 mg, 250 mg or 500 mg Compound 2 500 g Lactose USP, anhydrous or 200 g Stelotux powder HM 5 g Mix and fill as in Example 15a. Example 15c Compound 4 100 mg, 250 mg or 500 mg Compound 4 500 g Lactose USP, anhydrous or 200 g Stelotux powder HM 5 g Mix and fill as in Example 15a. Example 16 Tablet Example 16a Compound 1 100mg, 200mg or 500mg Compound 1 500g Corn starch NF 200.0g Cellulose, microcrystalline 46.0g Stelotex powder HM 4.0g Purified water appropriate amount or 300.0ml Corn starch, cellulose and Compound 1 mixed in a planetary Combine together in the machine and mix for 2 minutes. Add water to this combination and mix for 1 minute. The resulting mixture is spread on a tray and dried in a hot air oven at 50°C until the humidity reaches 1 to 2%. The dry mixture is then pulverized in a Fitzmill and passed through #RH2B film on medium speed. The Sterotex powder is added to a portion of the mixture and passed through a #30 sieve, which is returned to the original powdered mixture, and the whole is blended by rotating the cylinder for 5 minutes.
Compressed tablets of the total mixture of 150 mg, 375 mg and 750 mg respectively are formed with appropriate size punches as tablets containing 100 mg, 250 mg or 500 mg. Example 17 Suppository Example 17a Compound 1 250mg, 500mg or 1000mg/3g Compound 1 250mg 500mg 1000mg Polyethylene glycol 1540
1925mg 1750mg 1400mg Polyethylene glycol 8000
825mg 750mg 600mg Polyethylene glycol 1540 and polyethylene glycol 8000 are melted together at 60°C and compound 1 is dissolved into this melt. Place this entire mixture into a mold at 25°C to make a suitable suppository. Example 17b Compound 2 250, 500, 1000mg/3g Compound 2 250mg 500mg 1000mg Polyethylene glycol 1540
1925mg 1750mg 1400mg Polyethylene glycol 8000
825mg 750mg 600mg Prepared similarly to Example 17a above.
ïŒ ã¢ãããŒã æ§åè硬åçã®çç¶ãæå¶ãŸãã¯
軜æžããã«å
åãªæ²»çåŠçæå¹éã«ãŠååšãã26
âããããã·ã³ã¬ã¹ãããŒã«ã掻æ§æåãšããŠå«
æããããšãç¹åŸŽãšãããã¢ãããŒã æ§åè硬å
çã®çç¶æå¶ãŸãã¯è»œæžçšå»è¬è£œå€ã
1. Present in a therapeutically effective amount sufficient to suppress or alleviate symptoms of atherosclerosis26
- A pharmaceutical preparation for suppressing or alleviating symptoms of atherosclerosis, characterized in that it contains hydroxycholesterol as an active ingredient.
Claims (1)
èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®çµæç©ã ïŒ äžèšã¢ã·ã«ãšã¹ãã«ãå®æ¯éŠé žãšã¹ãã«ã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®çµæç©ã ïŒ äžèšååç©ãïŒâβââãªããã©ãã·ã«ã
ã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããã®ãã¹ããªã«ãš
ã¹ãã«ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®çµæç©ã ïŒ äžèšååç©ãïŒâβââãªããã©ãã·ã«ã
ã¢ãŸãŒã«âïŒâã«ã«ããã·ã¢ããâ5â²âãã¹ããš
ãŒãã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®çµæç©ãThe composition according to claim 1, which is a derivative of the compound. 4. The composition of claim 3, wherein the acyl ester is an acetate ester. 5. The composition of claim 3, wherein the acyl ester is a benzoic acid ester. 6. The composition of claim 1, wherein said compound is a phosphoryl ester of 2-β-D-ribofuranosylthiazole-4-carboxamide. 7. The composition of claim 1, wherein said compound is 2-β-D-ribofuranosylthiazole-4-carboxyamido-5'-phosphate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32445581A | 1981-11-24 | 1981-11-24 | |
| US324455 | 1981-11-24 | ||
| JP6002572A JP2522225B2 (en) | 1994-01-14 | 1994-01-14 | Vehicle air conditioner |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5892613A JPS5892613A (en) | 1983-06-02 |
| JPH0457646B2 true JPH0457646B2 (en) | 1992-09-14 |
Family
ID=26335980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57114150A Granted JPS5892613A (en) | 1981-11-24 | 1982-07-02 | Anti-malignant tumoral |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5892613A (en) |
-
1982
- 1982-07-02 JP JP57114150A patent/JPS5892613A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5892613A (en) | 1983-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3007058C (en) | Cytarabine conjugates for cancer therapy | |
| EP1323423B1 (en) | Combined preparation comprising a morpholinyl anthracycline derivative and a topoisomerase II inhibitor | |
| JPH02304084A (en) | Antiviral drug | |
| JP4824235B2 (en) | Drugs that protect against oxidative toxic substances, especially cardiotoxic substances | |
| JPH10505578A (en) | Pyrimidine nucleotide precursors for the treatment of systemic inflammation and inflammatory hepatitis | |
| EP1503756B1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| KR100315890B1 (en) | pyrimidine nucleotide precursor for treatment of systemic inflammation and inflammatory hepatits | |
| US20050171051A1 (en) | Pharmaceutical composition for diabetic neuropathy | |
| US4680285A (en) | Treatment of malignant tumors with 2-(β-D-ribofuranosylthiazole-4-carboxamide related compounds | |
| JPH0457646B2 (en) | ||
| EP0054432B1 (en) | Use of 2-beta-d-ribofuranosylthiazole-4-carboxamides for the manufacture of medicaments inhibiting malignant tumors | |
| CN111518157B (en) | Triptolide derivative and preparation method and application thereof | |
| WO1991017751A1 (en) | Orally administrable gallium compositions and methods of treatment therewith | |
| CA1326849C (en) | Treatment of malignant tumors with 8 chloroadenosine 3',5'-cyclic phosphate, and preparation thereof | |
| JP2687398B2 (en) | Aldose reductase inhibitor | |
| US5763419A (en) | Treatment of malignant tumors with 8-chloroadenosine 3',5'-cyclic monophasphate | |
| US5955498A (en) | Agent for prophylaxis and therapy of diseases | |
| JP4130700B2 (en) | Antitumor agent-containing composition | |
| JPS58105918A (en) | Antimalignant tumoral | |
| US12064445B2 (en) | Cytarabine conjugates for cancer therapy | |
| US5869525A (en) | Ascorbic acid drugs for intracerebral administration | |
| CN103260614B (en) | Conjoint therapy | |
| NZ199265A (en) | 2-b-d-ribofuranosylthiazol-4-carboxamide esters and antitumour compositions | |
| AU2004244987A1 (en) | Method of mitigating the adverse effects of IL-2 | |
| WO1998043990A1 (en) | Gallic acid ester derivatives and drugs containing the same as the active ingredient |